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ABSTRACT 
 
   Wheezing in infants when they have a lower respiratory tract infection is not uncommon. 
However, some of these wheezing infants, specifically those requiring hospitalization, are at 
high risk of later asthma. Identifying at-risk infants would be helpful for monitoring and 
focusing treatment on the right subjects. 
      In 1992-1993, 100 infants aged 1-23 months were hospitalized for wheezing associated with 
respiratory tract infection. The baseline data, blood specimens and nasopharyngeal aspirates 
(NPAs) were collected on entry to the study. As an acute intervention, the clinical responses to 
racemic adrenaline and salbutamol were evaluated.  The asthma and allergy status of the 
children have been clinically evaluated at the median ages of 4.0 and 7.2 years. In 2004, on 
average 11 years after the hospitalization for wheezing, 81/100 children attended the clinical 
follow-up in teenage years, i.e median age of 12.3 years (range 10.9-13.7). Symptoms 
suggestive of asthma and allergy were recorded and studies on allergy, baseline lung function 
and bronchial hyper-reactivity (BHR) were performed.  
   Teenage asthma was present in 40 % (32/81) of the children, and 25 % (20/81) of the children 
had asthma at all three visits and were considered to have persistent childhood asthma (PCA). 
Most of the children with teenage asthma (90%) or PCA (95%) were sensitized to at least one 
allergen. 
   Early factors predicting both teenage asthma and PCA were atopic dermatitis (adjusted odds 
ratios, aORs 3.5 and 4.5, respectively) and the presence of serum specific immunoglobulin E 
(sIgE) to inhalant allergens (aORs 11.3 and 13.1, respectively) and to wheat (aORs 20.2 and 
9.7). Respiratory syncytial virus (RSV) aetiology of early wheezing was associated with a 
restrictive pattern of lung function, and early atopy and maternal smoking during pregnancy 
were associated with BHR. Though minor evidence was found that the children with later PCA 
may respond better to bronchodilators than those children with no PCA, the overall clinical 
responses to bronchodilators did not differ between these groups. Early exposures to cats and 
dogs were not associated with the prevalence of teenage asthma or PCA or atopic sensitization 
in infancy or at teenage. Neutrophil derived serum myeloperoxidase was not associated with 
later asthma. 
   Children with teenage asthma and children with PCA had higher blood eosinophil (B-EOS) 
count at the time of wheezing in infancy than their counterparts who did not develop teenage 
asthma (median 0.41x109 cells/L vs. 0.17x109, p=0.027) or PCA (0.53x109 vs. 0.20x109, p= 
0.006). The level of eosinophil cationic protein (ECP) in NPA (NPA-ECP), but not in serum (S-
ECP), was higher in children with PCA than in children with no PCA (926 ng/g vs. 347 ng/g, 
p=0.013). At least one eosinophilic marker measured in infancy, was elevated (B-EOS ≥0.45 x 
109 cells/L or NPA-ECP ≥815.0 ng/g or S-ECP ≥20.0μg/L) in 61% of the children with teenage 
asthma and in 75% of the children with PCA. In addition, elevated NPA-ECP predicted PCA 
independently of the presence of early atopic dermatitis (aOR 4.09).  
   In conclusion, a quarter of children hospitalized for wheezing in infancy will suffer from 
persistent asthma during childhood, and as many as 40 % will have asthma in teenage years. 
The features known to be related to chronic bronchial asthma, such as eosinophilic 
inflammation, atopic dermatitis and sensitization to inhalant allergens, are present already in 
some wheezing infants and in these children, their presence is predictive of later asthma. 
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TIIVISTELMÄ 
 
   Varhaislapsuudessa uloshengitysvaikeus on yleistä alahengitystieinfektion aikana. 
Pikkulapsena sairastettu uloshengitysvaikeus ennustaa myöhempää astmaa ja riski sairastua 
astmaan on erityisen suuri jos uloshengitysvaikeus on johtanut sairaalahoitoon. Suuressa 
astmariskissä olevien pikkulasten tunnistaminen varhain olisi tärkeää, jotta lääkehoito ja tarkka 
seuranta osattaisiin kohdistaa oikein.  
   Tähän tutkimukseen otettiin 100 alle 2-vuotiasta lasta, joita hoidettiin sairaalassa 
alahengitystieinfektioon liittyvän uloshengitysvaikeuden vuoksi vuosina 1992-1993. Sairaalaan 
ottovaiheessa kerättiin tarkat tiedot lasten varhaisvaiheista ja lähisukulaisten atooppisista 
sairauksista sekä otettiin verinäytteitä ja nenänielun imulimanäytteitä (NPA). Lisäksi 
alkuvaiheeseen liitettiin lääkeinterventio, jossa selvitettiin kliinisin vastein raseemisen 
adrenaliinin ja albuterolin tehoa. Varhaisvaiheiden jälkeen lapset on tutkittu kliinisesti noin 4 ja 
7 vuoden ikäisinä astman ja allergioiden esiintyvyyden selvittämiseksi. Vuonna 2004, noin 11 
vuotta varhaisen sairaalahoitoa vaatineen uloshengitysvaikeuden jälkeen, 81/100 lasta osallistui 
seurantakäynnille teini-iässä, 11-14-vuotiaina.  Tällä seurantakäynnillä kartoittettiin allergia- ja 
astmaoireet sekä tutkittiin herkistymistä allergeeneille ja keuhkojen toimintaa sekä 
keuhkoputkien supistumisherkkyyttä. 
   Lapsista 40 %:lla (32/81) oli astma ja 25 %:lla (20/81) lapsista oli astma kaikilla kolmella 
seurantakäynnillä (krooninen astma). Suurin osa astmaatikoista (90 %) ja kroonisista 
astmaatikoista (95 %) oli herkistynyt vähintään yhdelle hengitystieallergeenille. 
   Varhaiset tekijät, jotka ennustivat astmaa ja kroonista astmaa, olivat atooppinen dermatiitti 
(vakioidut oddsien suhteet, vORs, 3.5 ja 4.5, tässä järjestyksessä), seerumin spesifinen 
immunoglobuliini E (sIgE) inhalaatioallergeeneille (vORs 11.3 ja 13.1) ja vehnälle (vORs 20.2 
ja 9.7). Respiratory syncytial virus (RSV) varhaisen uloshengitysvaikeuden aiheuttajana liittyi 
restriktiiviseen vt-spirometrialöydökseen ja varhainen atopia sekä äidin raskauden aikainen 
tupakointi keuhkoputkien lisääntyneeseen supistumisherkkyyteen. Vaikka viitteitä sille, että 
tulevat astmaatikot reagoisivat paremmin keuhkoputkia laajentaville lääkkeille kuin ei-
astmaatikot löytyi, kokonaisuudessaan näiden ryhmien vasteet varhaiselle interventiolle eivät 
eronneet toisistaan. Varhainen altistuminen kissan ja koiran allergeeneille ei lisännyt astman, 
kroonisen astman tai allergeeneille herkistymisen riskiä. Varhaisen alahengitystieinfektion 
aikana mitattu seerumin myeloperoxidaasi ei ollut yhteydessä myöhempään astmaan. 
    Astmaatikoilla ja kroonisilla astmaatikoilla oli enemmän veren eosinofiilisiä soluja sairaalaan 
ottovaiheessa kuin ei-astmaatikoilla (mediaani 0.41 x 109 solua/l vs. 0.17 x 109, p=0.027) ja 
lapsilla, joilla ei ollut kroonista astmaa (0.53 109 vs. 0.20 109, p=0.006). Nenänielun imuliman, 
mutta ei seerumin, eosinofiilisen kationisen proteiinin (NPA-ECP) konsentraatio oli korkeampi 
kroonisilla astmaatikoilla verrattuna muihin lapsiin (926 ng/g vs. 347, p=0.013). Astmaatikoista 
61 %:lla ja kroonisita astmaatikoista 75 %:lla oli vähintään yksi eosinofiilisten solujen 
aktivaatiota osoitava merkkiaine (B-EOS≥0.45x109 cells/l tai NPA-ECP≥815.0 ng/g tai S-
ECP≥20 μg/L) koholla. Lisäksi koholla oleva NPA-ECP oli kroonisen astman itsenäinen 
riskitekijä (vOR 4.1). 
   Yhteenvetona voidaan todeta, että neljännekselle lapsista, jotka joutuvat varhaislapsuudessa 
sairaalahoitoon uloshengitysvaikeuden vuoksi, kehittyy krooninen astma ja jopa 40 %:lla on 
astma teini-iän kynnyksellä. Astmaan tunnetusti liittyvät atooppinen ihottuma, herkistyminen 
hengitystieallergeeneille ja eosinofiilinen tulehdus ovat todettavissa jo osalla 
uloshengitysvaikeudesta kärsivistä pikkulapsista ja merkitsee riskiä sairastua myöhemmin 
astmaan.    
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1. INTRODUCTION 
 
   Wheezing, referring to expiratory breathing difficulty, is common during lower 
respiratory tract infection (LRTI) in early childhood: more than a third of all children 
suffer from wheezing by the age of three years (Taussig et al. 2003, Illi et al. 2004) and 
about two percent of all infants suffer from wheezing severe enough to warrant 
hospitalization (Korppi et al. 1986, Boyce et al. 2000, Koehoorn et al. 2008).  Viruses 
can be detected in the majority of wheezing infants, with respiratory syncytial virus 
(RSV) and rhinovirus being the most dominant agents (Kotaniemi-Syrjänen et al. 
2003b, Heymann et al. 2004, Jartti et al. 2004).  
   Recurrence of wheezing and the subsequent development of asthma are common after 
early childhood wheezing, especially after a wheezing episode requiring hospitalization 
(Martinez et al. 1995, Wennergren et al. 1997, Kotaniemi-Syrjänen et al. 2002, Piippo-
Savolainen et al. 2004, Sigurs et al. 2000 and 2005, Matricardi et al. 2008, Devulapalli 
et al. 2008). Small airway size and/or dysfunction in the regulation of airway tone seem 
to increase the risk of wheezing during LRTI in infancy and in childhood in otherwise 
healthy children (Turner et al. 2002, Taussig et al. 2003). For example, RSV-induced 
LRTI (RSV-LRTI) is a risk factor for subsequent wheezing up to the age of 11 years, 
but not any longer at age 13 (Stein et al. 1999b). Thus, the presence of wheezing in 
early puberty seems to be critical for the persistence of asthma.  
   Host, viral and other environmental factors are important determinants of the final 
outcome after early childhood wheezing (Castro-Rodriquez and Garcia-Marcos 2008, 
Singh et al. 2008, Martinez 2009). An atopic predisposition in infancy is a known risk 
factor for the development of asthma after wheezing in early childhood (Taussig et al. 
2003, Matricardi et al. 2008, Kotaniemi-Syrjänen and Korppi 2007, Piippo-Savolainen 
and Korppi 2009). In most studies on early-life risk factors for asthma, clinical or non-
specific markers of atopy, such as atopic dermatitis or elevated total serum 
immunoglobulin E (IgE), have been examined, and most studies have lacked either the 
determination of allergen-specific sensitization in infancy or the long-term follow-up 
revealing atopy becoming evident after infancy. There is recent epidemiologic evidence 
swhich uggests that early-life exposure to animals decreases subsequent allergy and 
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asthma (von Mutius 2007). In line with this, exposure to pets at the time of wheezing in 
infancy has not increased the risk of later asthma in the few long-term follow-up studies 
available (Goksör et al. 2006, Piippo-Savolainen et al. 2007a). 
      Rhinoviruses can provoke asthma exacerbations in adult asthmatics (Dougherty and 
Fahy 2009), and recent studies have stressed the role of rhinoviruses also during 
wheezing episodes in infants (Jartti et al. 2004, Kotaniemi-Syrjänen et al. 2003b, 
Jackson et al. 2008). Infants with rhinovirus induced wheezing seem to have an 
increased risk of suffering recurrent wheezing symptoms compared to wheezing 
induced by other viruses, like RSV (Lemanske et al. 2005). In many studies, this effect 
has been confirmed to continue until school age (Kotaniemi-Syrjänen et al. 2003b, 
Jackson et al. 2008), but there are no long-term follow-up studies with advanced viral 
diagnostic methods having been applied in infancy.  
   Eosinophilic inflammation is a characteristic feature of asthma, and it is often related 
to, and may even precede, the permanent structural changes in the airways (Barbato et 
al. 2006, Bush 2008). The age from one to three years has been suggested to be critical 
for the development of eosinophilic inflammation and the subsequent structural changes 
in the airways of young wheezing children at high risk of later asthma (Saglani et al. 
2005 and 2007).  Blood eosinophilia is a risk factor for later asthma in wheezy infants 
(Castro-Rodriquez et al. 2000, Ehlenfield et al. 2000, Just et al. 2008). However, there 
are no long-term follow-ups on the association between eosinophil activity in the blood 
or in the airways in wheezing infants and the risk of subsequent asthma. Neutrophils 
and their products seem to predominate in airway inflammation during acute viral 
wheeze in infancy (Kim et al. 2003, Marquet et al. 2008). In addition, neutrophils have 
an increased propensity to release myeloperoxidase (MPO), which is known to have the 
capability to damage epithelial cells (Haegens et al. 2008) and it also possesses pro-
inflammatory properties (Lau et al. 2005). The role of neutrophil mediators such as 
serum MPO, measured in wheezing infants, is obscure – little is known about whether 
they elevate the later risk of asthma.    
   A positive response to bronchodilating agents, specifically to β-adrenergic agents, is 
considered as a sign of asthma in older children and in adults. These agents have not 
been as effective in infants with virus-induced wheezing (Chavasse et al. 2002, King et 
al. 2004). However, clinical experience suggests that a subset of wheezing infants 
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benefits from treatment with β-adrenergic agents. It is unclear whether the positive 
responses, as measured by clinical parameters, may be useful in predicting later 
childhood asthma.  
   The main purpose of this thesis was to examine the risk factors, which are present 
during hospitalization for virus-induced wheezing in infancy, for teenage asthma and for 
asthma lasting through early childhood until at least teenage.  
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2. REVIEW OF THE LITERATURE 
 
 
2.1. Wheezing illnesses in early childhood  
2.1.1. Incidence of wheezing in early childhood 
 
   Wheezing symptoms are common in infancy: in the developed countries more than a 
third of all children will suffer from wheezing by the age of three years (Taussig et al. 
2003, Illi et al. 2004, Gillespie et al. 2006), and about 10-20 % of all children 
experience at least two wheezing episodes during the first years of life (Halken et al. 
1991, Castro-Rodriguez et al. 2000, Devulapalli et al. 2004, Kummeling et al. 2007). In 
infants with with atopic predisposition, i.e. asthma or atopy in at least one first-degree 
relative, the figure for wheezing in early life is even greater, more than 50 % (Kuiper et 
al. 2007).  
   About 2 % of all infants suffer from wheezing severe enough to warrant 
hospitalization (Korppi et al. 1986, Boyce et al. 2000, Koehoorn et al. 2008). The 
figures for recurrent wheezing are high after hospitalization for wheezing in infancy: 
during the following year as many as 70-75 % of these infants will experience at least 
one physician-diagnosed wheezing episode (Korppi et al. 1993, Reijonen et al. 1998), 
and approximately 40-50 % of the infants wheeze at least twice (Reijonen et al. 1998, 
Lehtinen et al. 2007).  
   Bronchiolitis is often defined as wheezing at age less than 24 months (American 
Academy of Pediatrics 2006, Scottish Intercollegiate Guidelines Network 2006). 
However, this group of wheezy infants is heterogeneous with respect to host, viral and 
environmental risk factors evoking the wheezing symptoms in infancy, as well as in 
how this will impact on later childhood outcome (Jartti et al. 2009). Thus, identifying 
children at high risk of later asthma, and on the other hand, those who really are not at 
risk is clinically very important but challenging. 
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2.1.2. Viral recovery rates of wheezing illnesses and viral detection by molecular 
and non-molecular methods    
   Until the 1990s, viral diagnosis of wheezing illnesses was based on non-molecular 
methods, and viral recovery rates for wheezing in infancy were often below 50 % 
(Table 1) and for asthma exacerbations only about 10-30 % (Clarke et al. 1979, 
Pattemore et al. 1992). Non-molecular methods include conventional cell cultures 
(Ginocchio et al. 2007) and faster shell vial cultures (Ginocchio et al. 2007). Viral 
protein antigens can be detected directly in clinical specimens by immune fluorescence 
(IF)-based methods or by enzyme immunoassays (EIA) (Ginocchio et al. 2007, Mahony 
et al. 2008, Loens et al. 2009). A variety of serological tests including the 
hemagglutination inhibition test, complement fixation (CF) and EIA can be used for 
testing for antibodies in serum samples (Mahony 2008). The sensitivities of non-
molecular methods vary greatly, e.g. depending on targeted viruses and age of 
specimens, and a combination of methods is often necessary to improve the diagnostics 
(Ginocchio et al. 2007, Mahony et al. 2008). 
   With the development of more sensitive molecular nucleic acid amplification 
techniques, multiple studies have shown that 80-95 % of wheezing in infancy (Table1) 
as well as most asthma exacerbations in children are induced by respiratory viruses 
(Johnston et al. 1995, Freymuth et al. 1999, Jartti et al. 2004, Grissel et al. 2005). These 
novel techniques include the polymerase chain reaction (PCR), which has led to the 
discovery of new viruses and a re-evaluation of the role of old viruses in LRTIs in 
children (Korppi 2008). Since most respiratory viruses are RNA-viruses, reverse 
transcriptase PCR (RT-PCR), in which nucleic acid is reverse transcribed into cDNA, is 
usually applied to detect respiratory viruses. 
   Different kinds of specimens can be used in respiratory virus diagnostics e.g. 
nasopharyngeal aspirate (NPA), nasopharyngeal wash, nasopharyngeal swab, 
oropharyngeal swab, sputum, tracheal aspirates and bronchoalveolar lavage (Ginocchio 
et al. 2007, Loens et al. 2009). It has been proposed that NPA is the optimal specimen to 
detect respiratory viruses by both non-molecular and molecular methods (Loens et al. 
2009). 
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2.1.3. Infectious triggers of wheezing in infancy 
 
Respiratory syncytial virus (RSV) 
   RSV (family Paramyxoviridae) is a single-stranded enveloped RNA-virus and the 
most common aetiological agent causing expiratory wheezing in infancy (Table 1). 
There are two subtypes of RSV, RSV A and B, wich possess antigenic differences and 
genetic diversity in the proteins (Ogra 2004). Important structural proteins include the 
fusion (F) protein and the attachment (G) protein (Ogra 2004). RSV accounts for about 
40-70 % of the wheezing episodes in children aged less than three years (Table1), with 
detection rates being usually more than 50 % in children aged less than one year 
(Table1). During the winter months in temperate climates, RSV causes more than 60 % 
of the wheezing episodes in infants (Marguet et al. 2009, Mansbach et al. 2008). Nearly 
all children have been infected by the age of three years, and repeated, though clinically 
mild, infections are possible (Glezen et al. 1986, Ogra 2004). A seasonal variability is 
typical for RSV: in temperate climates the peak prevalence is in winter, with most 
infections occuring between late fall and early spring (Yusuf et al. 2007). In tropical 
climates, the virus can be detected all year round, and peaks are related to low 
temperatures (Stensballe et al. 2003). In northern Europe, RSV epidemics follow a 
regular long-term biannial pattern. For example in Finland, a minor RSV epidemic in 
every other spring is followed by a major epidemic in the following autumn and winter 
(Terlatskaia-Ladwig et al. 2005, Jartti et al. 2004). Children at the highest risk for 
suffering more severe symptoms are infants aged less than six months, particularly 
premature infants, and infants with bronchopulmonary dysplasia, congenital heart 
disease or immunodeficiency disorders (Boyce et al. 2000).    
 
Picornaviruses 
   Rhinovirus (family Picornaviridae) is known as the common cold virus, but many 
studies using molecular techniques, specifically RT-PCR, have shown that rhinoviruses 
cause up to 40 % of wheezing episodes in infants and are the second most important 
aetiological agent after RSV in early wheezing (Table1). Rhinovirus is a dominant 
pathogen in wheezing illnesses in older children and adults and accounts for about 65 % 
of the respiratory viruses identified in these cases (Dougherty and Fahy 2009, 
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Friedlander 2005). Rhinoviruses are single-stranded non-enveloped RNA viruses, and 
more than 100 rhinovirus serotypes have been identified (Kelly and Busse 2008). The 
serotypes are classified into three phylogenetic groups, A, B and C (Kelly and Busse 
2008), which all are able to cause wheezing respiratory diseases (Kelly and Busse 2008, 
Miller 2009). However, serotypes A and C seem to be more common than serotype B, at 
least in hospitalized children (Miller et al. 2009). The intra-cellular adhesion molecule 
(ICAM) -1 is a cell-surface receptor, which binds most rhinovirus serotypes (Kelly and 
Busse 2008). Rhinoviruses circulate all year round, with peaks in late spring and early 
autumn in temperate climates (Carroll et al. 2008). Most children have been infected by 
rhinovirus by the age of two years (Carroll et al. 2008). 
   Enteroviruses (family Picornaviridae) are capable of causing wheezing LRTIs in 
infants (Jacques et al. 2008), and trigger up to 20 % of the wheezing episodes in infancy 
(Table1). Enteroviruses have also been found in the airways of older children with 
symptomatic asthma, especially during the summer periods (Rawlingson et al. 2003, 
Jartti et al. 2004). Enteroviruses are single-stranded non-enveloped RNA viruses 
(Mahony 2008) and the non-polio-enteroviruses are divided into four species, A-D 
(Mahony 2008). There are almost 100 enterovirus serotypes (Jacques et al. 2008), and 
many different strains have been isolated from specimens collected from the respiratory 
tract (Jacues et al. 2008). In temperate climates, most enterovirus infections occur in 
spring, summer and autumn, with infections lasting into the winter (Mahony 2008, 
Jacques et al. 2008).  
   After the age of 12 months, the role of picornaviruses becomes more dominant in 
childhood wheezing, and rhinoviruses and enteroviruses together account for about 65 
% of all cases (Jartti et al. 2004). 
 
Human metapneumovirus (hMPV) 
   Human metapneumovirus (family Paramyxoviridae) is a single-stranded enveloped 
RNA-virus, which has probably been circulating for decades, but was not discovered 
until 2001 (Kahn 2006, Mahony 2008).  At least two distinct genotypes cause 
respiratory tract diseases in humans (Kahn 2006). hMPV is related to RSV, and the 
clinical manifestations of these viruses are indistinguishable (Kahn 2006, Mahony 
2008). The age-related incidence of hMPV infection is highest in children aged less than 
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two years (Heikkinen et al. 2008), and most children have been infected by the age of 
five years (Kahn 2006). hMPV causes up to 16 % of all wheezing episodes in infancy 
(Table 1), and is second or third to RSV and rhinovirus as a cause of bronchiolitis 
(Table1, Wolf et al 2006). Co-infections with RSV and other viruses are rather common 
(Kahn 2006, Xepapadaki et al. 2004). hMPV has a worldwide distribution, and in 
temperate climates, it is detected throughout the year, but it circulates mainly in the late 
winter and spring, and often coincides with or follows the peaks of RSV epidemics 
(Kahn 2006).  
 
Adenovirus 
   Adenoviruses (family Adenoviridae) are double-stranded non-enveloped DNA viruses 
with more than 50 serotypes, which are classified into six subtypes (A-F) (Mahony 
2008). Type C seems to be the most common subtype found in the respiratory tract 
(Echavarria 2006). Adenoviruses circulate all year round, but infections are most 
frequent in late winter and early spring (Mahony 2008). Most adenovirus infections 
occur in early life (Mahony 2008) and can be considered as being responsible for up to 
20 % of wheezing episodes in infancy (Table1). 
 
Coronavirus 
   Coronaviruses (family Coronaviridae) are single-stranded, large and enveloped RNA 
viruses, which are found in up to 8 % of the specimens obtained from wheezing infants 
(Table 1). There are two main serogroups, group I includes coronaviruses 229E and 
NL63 and group II coronaviruses OC43, SARS and HKU1 (Mahony 2008).  
Coronaviruses 229E and OC43, identified in the mid 1960s, are capable of causing not 
only mild (i.e. common cold) but also severe (i.e. bronchiolitis and pneumonia) 
respiratory tract infections (Mahony 2008). A novel coronavirus, SARS, associated with 
severe acute respiratory syndrome, was discovered in 2003 (Williams 2005). The most 
recently discovered coronaviruses, NL63 and HKU1, have been found to cause a variety 
of respiratory tract diseases worldwide including wheezing-associated illnesses 
(Mahony 2008, Ebihara 2005). In the temperate climates, coronavirus infections occur 
mainly in the winter months, often jointly with other viruses (Mahony 2008).  
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Parainfluenza and influenza viruses 
   Parainfluenza viruses (family Paramyxoviridae) are single-stranded enveloped RNA-
viruses, and four parainfluenzavirus serotypes (1-4) cause symptomatic respiratory 
infections (Mahony 2008), being responsible for up to 13 % of wheezing episodes in 
infants (Table1).  Parainfluenza viruses circulate all year round, and type 3 is able to 
cause most of the severe lower respiratory tract infections in infants, and is most 
prevalent in the spring and winter months (Mahony 2008).   
   Influenza viruses (family Orthomyxoviruses) are single-stranded enveloped RNA-
viruses, which cause annual epidemics in temperate climates (Mahony 2008, Chen and 
Deng 2009). The surface glycoproteins of influenza virus, hemagglutinin (HA) and 
neuraminidase (NA), are highly variable which complicates the development of 
vaccines (Chen and Deng 2009). Pandemics may follow the emergence of a new virus 
with a novel HA and NA combination (Chen and Deng 2009). The rates of wheezing 
episodes associated with influenza virus vary greatly, depending on the attack rates in 
the general population (Rojo et al. 2006). In temperate climates, epidemics occur during 
the winter months and last from three to eight weeks (Mahony 2008, American 
Academy of Pediatrics, Committee on infectious diseases 2008).  There are three genera 
within the influenza family (A, B and C) and only A and B viruses are capable of 
causing significant diseases (Carrat and Flahaut 2007). Influenza A virus infections tend 
to occur at a younger age than influenza B virus infections (Rojo et al. 2006, Peltola et 
al. 2002), and children younger than two years are at the highest risk of LRTI (Rojo et 
al. 2006). Influenza viruses cause up to 5 % of wheezing episodes in infants aged less 
than three years (Table 1).  
 
Bocavirus 
   Human bocavirus (family Parvoviridae) is the most recently discovered wheezing-
associated respiratory tract virus (Allander et al. 2001). Bocavirus is a single-stranded 
non-enveloped DNA-virus with two distinct genotypes circulating worldwide (Mahony 
2008). Infections have been diagnosed by molecular methods and by serology, but 
bocavirus has not been isolated in cell cultures (Mahony 2008, Kantola et al. 2008). 
Bocavirus has been associated with varying degrees of respiratory illnesses, ranging 
from common cold to bronchiolitis and pneumonia (Arnold et al. 2006, Bastien et al. 
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2007, Mahony et al. 2008). The symptoms most commonly associated with bocavirus 
infections are cough, fever and rhinitis (Bastien et al. 2007). In several studies, 
bocaviruses have been most prevalent in children aged less than three years (Mahony 
2008). It has been reported that bocavirus is present in 20 % of the wheezing children at 
that age (Jartti et al. 2004), but most of the bocavirus findings have been co-infections 
with other viruses (Allender et al. 2007), and the role of bocavirus as a true pathogen 
has been questioned (Allender et al. 2007).  However, viral loads have been high if 
bocavirus has been the only detected virus and antibody responses have been associated 
with high numbers of viral copies in NPA detected by PCR, evidence for a causative 
role in wheezing infections (Allender et al. 2007). In addition, bocavirus is rarely 
detected in asymptomatic individuals (Mahony 2008). In temperate climates, bocavirus 
infections occur mainly in winter (Mahony 2008), but seasonality has not been found in 
all studies (Bastien 2007. 
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2.1.4. Mechanisms of virus-induced wheezing in infancy 
   Wheezing during respiratory virus infection means that viruses have infected the 
lower respiratory tract. Airway obstruction is caused by epithelial swelling and plugging 
of the airway lumen by mucus and cellular debris (Tuffaha and Busse 2001). In 
addition, viruses can enhance bronchial hyper-reactivity (BHR) by altering neural 
control mechanisms, mainly by inducing cholinergic activity and by inducing the 
release of neuropeptides (Tuffaha and Busse 2001, Gern and Lemanske 2003, Gern 
2008). The direct effects of the virus and infection-related immune responses both cause 
these changes, with the airway epithelial cells, granulocytes and lymphocytes being the 
main cells involved in the process (Tuffaha and Busse 2001, Gern 2008). The 
subsequent symptoms and signs include expiratory wheezing, tachypnea and hypoxia. 
 
Epithelial cells 
   The airway epithelial cells form the primary target of the viruses which infect the 
respiratory tract (Gern and Lemanske 2003, Gern 2008). Respiratory viruses, especially 
RSV, can cause direct lung injury by replication in the epithelium (Gern and Lemanske 
2003, DeVincenzo 2007), leading to epithelial oedema and shedding which together 
with mucus production can provoke wheezing symptoms (Gern 2008). Epithelial 
damage may cause enhanced allergen exposure since it can increase permeability of the 
mucosal layer (Gern 2008). Rhinoviruses usually are responsible for minor cellular 
damage, i.e. the mechanisms leading to the symptoms are mainly immunological (Kelly 
and Busse 2008). On the other hand, persistence of rihonoviruses in the lower airway 
epithelial cells of recurrently wheezing infants has been reported (Malmström et al. 
2006). Viruses bind to receptors, RSV mainly to Toll-like receptors (TLRs) (Murawski 
et al. 2009) and rhinovirus mainly to ICAM-1 receptors (Kelly and Busse 2008). Host 
cell recognition of viral antigens leading to viral replication in epithelial cells leads to 
activation of transcription factors of several cytokines and chemokines, which attract 
leucocytes to the site of inflammation (Schuh et al. 2003, Gern and Lemanske 2003, 
Kelly and Busse 2008).  
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Granulocytes, monocytes and macrophages 
   Activation of cytokines and chemokines is followed by immune cell influx and 
activation (Tuffaha and Busse 2001, Gern 2008). Neutrophils are the most common cell 
type in virus-induced respiratory tract infection in wheezing infants and are present also 
in the respiratory secretions of subjects with acute asthma (Kim et al. 2003, Marquet et 
al. 2008, Barbato et al. 2001, Norzila et al. 2000). Sputum neutrophils as well as their 
degranulation products, such as elastase, interleukin (IL)-8 and MPO, are likely to 
contribute to airway obstruction by mucus secretion and by further secretion of 
chemokines and cytokines (Gern 2008, Jaovisidha et al. 1999).   
   Mononuclear cells, such as macrophages and dendritic cells, are important cells in the 
early responses to respiratory viruses and these cells secrete adhesion molecules such as 
ICAM-1 and pro-inflammatory cytokines such as IL-1, IL-8, tumor necrosis factor 
alpha, interferon (IFN)-γ, IFN- α, and monocyte inflammatory protein -1α (Gern 2008, 
Kelly and Busse 2008, Tuffaha and Busse 2001). These products are important 
mediators of inflammation and they act to attract and recruit further inflammatory cells, 
but type 1 IFNs, such as IFN-α, may also limit viral spread and take part in the recovery 
process (Gern 2008, Kelly and Busse 2008).  
   There is evidence that eosinophils can also be activated during respiratory tract 
infection (Tuffaha and Busse 2001). Eosinophil activation during rhinovirus infection is 
common (Gern 2008, Kelly and Busse 2008), and an eosinophil-positive subgroup has 
been identified in infants suffering from RSV-induced bronchiolitis (Kim et al. 2003). 
The infected epithelial cells secrete a mediator called regulated upon activation normal 
T-cell expressed and secreted (RANTES), which is an important chemotactic factor in 
the activation of eosinophils (Kelly and Busse 2008). Eosinophil cationic protein (ECP), 
secreted by eosinophils, may even have antiviral properties (Kelly and Busse 2008). On 
the other hand, elevated sputum eosinophils, seen often in asthmatic subjects when there 
are no infections, may also enhance an individual′s susceptibility to suffer a rhinovirus 
infection (Kelly and Busse 2008).  
 
Lymphocytes 
   Cell-mediated immune responses are involved in virus-induced wheezing in infancy 
(Tuffaha and Busse 2001, Gern 2008, Kelly and Busse 2008). Natural killer T-cells, 
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CD8+ cytotoxic T-cells (T-killer) and CD4+ T-cells (T-helper) are involved in virus-
induced wheezing in infancy during the early stages of the illness (Tuffaha and Busse 
2001). During viral infection, CD8+ T-cells produce IFN-γ which has an ability to lyse 
infected cells (Tuffaha and Busse 2001). CD4+ T-cells differentiate into T-helper (Th) 1 
cells or Th2 cells depending on cytokines produced by monocytes or antigen presenting 
cells (Tuffaha and Busse 2001, Pinto et al. 2006). Viral infections typically induce Th1-
type cells, which produce cytokines, including IFN-γ and IL-2, two cytokines which are 
essential in cell-mediated immunity (Tuffaha and Busse 2001, Pinto et al. 2006, Gern 
2008, Kelly and Busse 2008).  The Th2 cells tend to produce other cytokines including 
IL-4 and IL-5, which are typical of asthma and allergy and important in humoral 
immunity and in the immediate-type hypersensitivity (Pinto et al. 2006, Smyth and 
Openshaw 2006).  
   The first B-cell response to a respiratory tract virus infection is the generation of 
mucosal IgA within a few days this being followed by the production of specific IgM 
and IgG antibodies (Kelly and Busse 2008). Thus, lymphocytes serve to clear infected 
epithelial cells and to limit the extent of infection (Gern 2008).  
 
2.1.5. Factors contributing to susceptibility to virus-induced wheezing in infancy 
 
Age, sex and co-morbidity 
   Population-based birth cohort studies have shown that wheezing during lower 
respiratory tract infection is most common during first year of life (Matricardi et al. 
2008, Polk et al. 2004, Sandin et al. 2004, Taussig et al. 2003). In community-based 
studies, the prevalence of wheezing has been 18-32%, 9-17% and 4-12% in the first, 
second and third year of life, respectively (Taussig et al. 2003, Matricardi et al. 2008). 
Bronchiolitis cases occur most frequently in the first months of life (Koehoorn et al. 
2008, Scottish Intercollegiate Guidelines Network 2006).  In addition, younger infants 
are at higher risk than older infants for requiring hospitalization for virus-induced 
wheezing (Scottish Intercollegiate Guidelines Network 2006).  In infancy, acute 
respiratory tract infections are equally common in males and females (Wright et al. 
1989, von Linstow et al. 2008). Nonetheless, wheezing is more common in boys, as 
observed both in epidemiological (up to 1.4-fold) and in hospital-based studies (1.4-2.3-
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fold) studies (Linneberg et al. 2006, Matricardi et al. 2008, Korppi et al. 1986, Reijonen 
et al. 1995, Koehoorn et al 2008, Marquet et al. 2009). Infants born prematurely or those 
who have congenital heart disease or chronic lung disease are at the highest risk of 
requiring hospitalization for bronchiolits (Scottish Intercollegiate Guidelines Network 
2006). 
    
Premorbid lung function 
   If the airway calibre is diminished at birth or in early life, LRTIs further reduce the 
calibre and thus facilitate wheezing symptoms. The measurement of maximal flow at 
the functional residual capacity (VmaxFRC) by the tidal rapid non-invasive 
thoracoabdominal compression technique has yielded most of the information about 
small airway function in young infants (Hoo et al. 2002, Taussig et al 2003). In these 
studies, diminished airway function, as reflected by a reduced length-adjusted VmaxFRC, 
has often preceded the first wheezing episode in infancy, and the length-corrected flows 
have been higher in female infants (Murray et al. 2002, Taussig et al. 2003).  The sex 
difference in length-adjusted VmaxFRC is significant during the first year of life (Hoo et 
al. 2002), and this may account for the early sex-related differences in airway structure 
and tone as well as by slower airway growth in boys (Hoo et al. 2002).  In addition, 
there is evidence that small infants have BHR to non-specific stimuli with diminishing 
reactivity with age (Taussig et al. 2003). Diminished lung function and BHR in infants 
before any LRTIs have been identified both in community-based studies and in a 
population with an atopic predisposition (Murray et al. 2002, Taussig et al. 2003).      
   In some studies, flow-limitation in infancy has been an independent risk-factor for 
wheezing illnesses, not related to known risk factors for asthma such as atopy or atopic 
predisposition (Turner et al. 2002, Turner et al. 2004). On the other hand, in a study 
which applied a plethysmographic method, infants with a family history of asthma 
displayed significantly reduced values of specific airway conductance compared to 
those with no family history of asthma (Dezateux et al. 1999). In addition, other factors, 
such as exposure to environmental tobacco smoke (ETS) and excessive weight gain, 
have been associated with reduced lung growth in infancy (Dezateux et al. 1999, Turner 
et al. 2008 and 2009).  
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Immunologic factors 
   Both innate immune responses, such as production of inflammatory mediators in 
response to host cell recognition of virus, and acquired immune responses, such as T-
cell and B-cell mediated responses, are important in protecting the host against virus 
infections (Heymann et al. 2005, Singh 2007).  Thus, variability in these immunologic 
responses may play an important role in host susceptibility to experience wheezing 
illnesses (Heymann et al. 2005, Oh 2006, Singh 2007, Juntti et al. 2009). Recent 
evidence has suggested that classical Th1-lympocyte cytokines, IL-2, IL-4, IFN-γ and 
IL-17, were virtually undetectable in secretions obtained from infants suffering from a 
severe infection caused by RSV (Welliver et al. 2007). In addition, high viral loads and 
activation of apoptotic mechanisms were associated with severe disease caused by RSV 
or influenza virus (Welliver et al. 2007). Thus, the pathogenesis of severe viral LRTI 
may be related to a failure to develop the appropriate cytotoxic T-cell response 
(Welliver et al. 2008), and this defect might be age-related, affecting mostly infants 
aged less than six months (Chung et al. 2007). A deficiency in the appropriate Th1-type 
responses is supported by the finding that infants with atopic predisposition exhibited an 
inverse correlation between cord blood IFN-γ responses of mononuclear cells and 
moderate to severe viral infections during the first year of life (Friedlander et al. 2005). 
In addition, excess Th2 type responses in atopic individuals may dimish viral clearance 
through suboptimal Th1 responses, and predispose patients to recurrent wheezing 
symptoms or asthma exacerbations (Papadopulos et al. 2002, Malmström et al. 2006). 
 
Genetic factors 
   Genetic loci that contribute to the variability in innate and acquired immune responses 
have been studied in order to evaluate the contribution of genetic predisposition to 
wheezing in infancy (Singh 2007). Studies performed thus far are limited and concern 
mainly RSV-associated disease in hospitalized infants and are based on the candidate 
gene approach (Singh 2007, Miyairi 2008). It has been estimated that the genetic 
contribution accounts for approximately 20 % of the variance in RSV disease severity 
(Miyairi 2008). Genes associated with viral entry to the host cell, genes encoding 
surfactant proteins functioning as recognition molecules, Th1 versus Th2 cytokine 
response genes, neutrophil response genes and genes associated with antibody responses 
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and with HLA type I antigens have been studied (Miyairi 2008). The evidence from 
these studies suggests that the genes related to the limitation of the extent of the 
infection, specifically genes associated with IFN system, are important (Miyairi 2008). 
Deficient Th1-type responses and excessive Th2-type responses have been reported in 
RSV disease, and IL-13 has been speculated to play an important role in the Th2 skew 
(Miyairi 2008, Forton et al. 2009). Polymorphisms in a region which is associated with 
increased IL-13 production, have been linked to asthma and atopy, and in a recent study 
also to increased risk of severe RSV bronchiolitis in infants aged less than six months, 
pointing to a common genetic component in these diseases (Forton et al. 2009). 
    There are only a few genetic studies on the susceptibility of early wheezing illnesses 
caused by respiratory tract viruses other than RSV.  However, there is evidence that 
immune responses as well as candidate genes in non-RSV bronchiolitis may be 
somewhat different than in RSV bronchiolitis. Expression of IFN-inducible genes has 
been higher in RSV bronchiolitis than in bronchiolitis caused by rhinovirus (Scagnolari 
et al. 2007).  IL-10 gene polymorphism, connected to asthma and atopy, was associated 
with severe rhinovirus bronchiolitis, but not to RSV-bronchiolitis at the age of less than 
six months (Helminen et al. 2008).      
 
Social and environmental factors 
   The population-based cohort studies have shown that exposure to infections as 
reflected in attendance to day-care or by the number of older siblings (Taussig et al. 
2003, Polk et al 2004, Sandin et al. 2004, Linneberg et al. 2005, Koehoorn et al. 2008), 
increases the risk of wheezing in early childhood.  In some studies, young maternal age, 
low maternal occupation level and low household income level have been related to an 
increased risk of wheezing episodes in early childhood (Koehoorn et al. 2008), but these 
associations have not been confirmed in all population-based cohorts (Linneberg et al. 
2006). In most studies, breastfeeding has been protective for wheezing illnesses in 
infancy (Wright et al. 2001, Oddy et al. 2003, Polk et al. 2004, Linneberg et al. 2006, 
Koehoorn et al. 2008). The role of exposure to ETS as a risk factor for early wheezing 
in infancy is evident, (Wright et al. 1991, Polk et al. 2004, Carrol et al. 2007, Håberg et 
al. 2007) and some studies have highlighted the association between maternal smoking 
during pregnancy and increased risk of wheezing in infancy (Linneberg et al. 2006, 
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Håberg et al. 2007). There are also other factors, such as exposure to air pollution (Ryan 
et al. 2005), dampness in the home environment (Emenius et al. 2004) and antibiotic 
exposure in early life (Kummeling et al. 2007), which have been linked to an increased 
risk of wheezing in infancy. 
   The social and environmental risk-factors for hospitalization due to virus-induced 
wheezing are mostly the same as those for wheezing not requiring hospitalization 
(Nielsen et al. 2003, Koehoorn et al. 2008). Exposure to ETS has been related to 
prolonged hospitalization (Chatzimichael et al. 2007, Marquet et al. 2009) and low 
oxygen saturation (Bradley et al. 2005), and maternal smoking during pregnancy has 
been associated with hospitalization for bronchiolitis (Nielsen et al. 2003, Koehoorn et 
al. 2008). The role of air pollutants in the risk of hospitalization for wheezing in infancy 
is not clear; exposure to air pollutants has been claimed to increase the risk, specifically 
in infants born prematurely (Karr et al. 2006) or in infants born just before or during the 
peak of an RSV seasonal epidemic (Karr et al. 2009).  
 
Atopy 
   Allergic individuals may have impaired antiviral responses, leading to more severe 
infections and further to wheezing (Papadopoulos et al. 2002, Gern 2008). It has been 
proposed that there exists a subgroup of infants with early respiratory allergy and 
eosinophilic inflammation in the airways, and this subgroup is particularly prone to 
wheeze during respiratory viral infections (Singh 2007, Gern 2008). Several studies 
have evaluated whether personal atopy or atopic predisposition increase the risk of 
wheezing illnesses in infancy. Population based-studies have found only weak (Illi et al. 
2004, Linneberg et al. 2006, Håberg et al. 2007) or even no associations (Martinez et al. 
1995, Sandin et al. 2004) between atopic manifestations or atopic predisposition and 
wheezing illnesses in infancy. In addition, the risk factors for atopic dermatitis seem to 
differ from those for wheezing in infancy suggesting that these two conditions have a 
different aetiology (Linneberg et al. 2006). However, some birth cohort studies have 
suggested that wheezing episodes are more frequent in infants with an atopic 
predisposition compared to infants with no atopic predisposition (Kuiper et al. 2007), 
and it is believed that other environmental factors, such as exposure to ETS, are 
particularly harmful in these predisposed infants (Kuiper et al. 2007). 
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   A few studies have found an association between early atopy or atopic predisposition 
and bronchiolitis requiring hospitalization (Carrol et al. 2007, Stensballe et al. 2006), 
but many studies have failed to detect any such association (Singh 2007). In a recent 
study, atopic manifestations in infants hospitalized for bronchiolitis increased wih age 
and were more common in infants with recurrent wheezing (Jartti et al. 2009). Thus, the 
question of whether there is a subgroup of wheezing infants with allergies and possible 
asthma-like inflammation in the airways, is unclear, and might depend on the age of the 
studied infants. 
 
Viral factors 
   In a birth cohort study conducted in infants with atopic predisposition, RSV caused 
more severe infections in infants than influenza A virus, parainfluenza virus or 
rhinovirus (Gern et al. 2002), which has also reported in small infants requiring hospital 
care (Marguet et al. 2009). There is some evidence that the presence of rhinovirus 
together with RSV increases the severity of bronchiolitis compared to RSV aetiology 
alone (Papadopoulos et al. 2002), but again some studies have failed to detect this 
relationship (Marguet et al. 2009). In other studies, there have been no differences in the 
clinical severity between rhinovirus induced bronchiolitis compared to RSV 
bronchiolitis in hospitalized infants (Kellner et al. 1989, Korppi et al. 2004a). However, 
infants hospitalized for rhinovirus induced wheezing were 6-24 months old, whereas 
infants with RSV aetiology of wheezing were less than 12 months old (Korppi et al. 
2004a). In addition, rhinovirus infection was more often associated with atopy, 
eosinophil activation (Korppi et al. 2004a, Jartti et al. 2007) and a more favourable 
response to oral prednisolone treatment than was the cases for wheezing related to RSV 
infection (Jartti et al. 2007).   
 
2.2. The prevalence of asthma symptoms in the child population, and the figures in 
short- and long-term follow-ups after early childhood wheezing 
   Approximately one-third of the children wheezing in the first three years of life 
continue to wheeze after the age of three years (Martinez et al. 1995, Kotaniemi-
Syrjänen et al. 2002, Matricardi et al. 2008). There are studies on population-based birth 
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cohorts, high-risk birth-cohorts and hospital-based cohorts revieling that even mild 
wheezing in infancy is a significant risk factor for wheezing and asthma later in life.  
 
2.2.1. Worldwide prevalence of asthma symptoms 
   According to the International Study of Asthma and Allergies in Childhood (ISAAC), 
the global prevalence of wheezing is 11.5 %, and frequent or severe asthma symptoms 
occur in 4.9 % of children at the age of six to seven years (Lai et al. 2009). The 
respective figures are 14.1 % and 6.9 % for 13-14 years old children (Lai et al. 2009). 
As seen in Table 2, the reported prevalence rates of asthma symptoms vary 
considerably; the rates of frequent asthma symptoms in the developed countries are 
highest in Australia and New Zealand (8.4-12.1%), and lowest in Europe (3.2-6.2%) 
including Finland (5.1%) and Sweden (3,4%). The lifetime prevalence of asthma was 
estimated to be 4.0 % in a non-selected population-based study in children aged 7-12 
years living in Kuopio, Finland, and an additional 3.0 % had displayed some evidence 
of asthma during the preceding year (Remes et al. 1996). 
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Table2. Prevalence of wheezing and frequent wheezing or severe asthma symptoms at the ages of 6-7 
and 13-14 years according to the ISAAC study (Lai et al. 2009) 
At the age of 6-7 years At the age of 13-14 years 
Region 
Current 
wheeze (%) 
Symptoms of frequent 
or severe asthma (%) 
Current 
wheeze (%) 
Symptoms of frequent 
or severe asthma (%) 
Global total 11,5 4,9 14,1 6,9 
Finlanda 
(Kuopio) - - 19,0 5,1 
Sweden 10,2 4,2 9,7 3,4 
Northern and 
Eastern Europe 8,7 3,2 9,7 3,8 
Western Europe 9,6 3,6 14,3 6,2 
North America 19,1 7,1 21,6 11,3 
Australia 20,0 8,4 30,6 12,1 
New Zealand 22,2 9,8 26,7 10,9 
a Data not available for the age of 6-7 years  
 
2.2.2. Short-term outcome after early childhood wheezing 
 
Wheezing symptoms and asthma 
     The prospective birth-cohort-studies, based usually on self-reported symptom-history 
or current symptoms, have shown that about 30-40 % of infants will have wheezing 
symptoms until pre-school age if they have wheezed in their first three years of life 
(Martinez et al. 1995, Sherriff et al. 2001, Sandin et al. 2004, Matricardi et al. 2008).  A 
retrospective population-based study, which applied a health-care specialist-confirmed 
diagnosis of bronchiolitis, revealed that 16 % of infants with an outpatient visit for 
bronchiolitis at less than one year of age had frequent wheezing symptoms or asthma at 
age 4-5.5 years (Carroll et al. 2009). In a high-risk birth cohort study, which included 
only children with an atopic predisposition, the risk of frequent symptoms or asthma at 
age six was 30-60 %, depending on the viral aetiology of early wheeze (Jackson et al. 
2008). 
   After hospital admission for wheezing in infancy 18-53 % of pre-school children 
experience frequent symptoms or asthma (Kotaniemi-Syrjänen and Korppi 2007, 
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Valkonen et al. 2009), and the prevalence of school-age asthma, at 7.6-9.5 years of age, 
has been 15-40 % (Korppi et al. 1994, Sigurs et al. 2000, Henderson et al. 2005, 
Kotaniemi-Syrjänen et al. 2005).  
 
Lung function 
   In the population-based lung function studies, it was found that pre-school children 
who continued to wheeze from infancy until six years of age had lower lung function in 
infancy, as indicated by their values for VmaxFRC, compared to those who had never 
wheezed (Martinez et al. 1995). In another population-based study, a third of the early 
wheezers had BHR to histamine at the age of seven years, and this figure rose to more 
than 50 % in those children with both early and current wheeze, but early wheezing was 
not a significant predictor of BHR at early school age (Illi et al. 2006). 
   There is evidence that children hospitalized for RSV bronchiolitis at less than one year 
of age have reduced lung function, as measured by flow volume spirometry (FVS),  at 
age seven years compared to age-matched controls (Fjaerli et al. 2005). In addition, a 
reduction in lung function and increased BHR have been observed at school age in 
children hospitalized for virus-induced bronchiolitis when they were less than two years 
of age compared to controls (Korppi et al. 1994).  Further, seen in the present cohort 
followed up until early school age, 23 % of the children who had been hospitalized for 
virus-induced bronchiolitis in infancy exhibited reduced indices in FVS and 13 % had 
BHR to exercise, and BHR was significantly associated with rhinovirus aetiology of 
early wheezing (Kotaniemi-Syrjänen et al. 2008). 
 
2.2.3. Long-term outcome after early childhood wheezing 
 
Wheezing symptoms and asthma  
   In the birth cohort studies, about 30-40 % of the children who suffered wheezing at 
less than three years of age have continued to display symptoms until the age of 11-13 
years (Morgan et al. 2005, Matricardi et al. 2008), but some birth cohort studies have 
reported lower figures, 13-24 %, for wheezing symptoms (Sporik et al. 1991, Lodrup 
Carlsen et al. 2006). There are only few birth cohorts which have been followed up until 
adulthood. In the birth cohort study from Tucson, Arizona, one third of the early 
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wheezers were regarded as asthmatic at the age of 22 years, and an additional third of 
early wheezers had inactive asthma, i.e. an asthma diagnosis but no current symptoms 
(Stern et al. 2008). In another birth cohort study in subjects with an atopic 
predisposition, 38 % of infants with wheezing before the age of two years still were 
displaying symptoms at the ages of either 11 or 22 years (Rhodes et al. 2001).    
   There are only few long term follow-up studies after hospitalization for wheezing in 
infancy. Wheezing or asthma has been demonstrated in 17-39 % of the children 
followed up to 10-13 years of age after hospitalization for wheezing in infancy (Table 
3), and these figures are higher than in controls or in the general population in all of the 
studies. There are only two prospective follow-up studies after hospitalization for early 
childhood wheezing which have continued until adulthood (Piippo-Savolainen et al. 
2004, Goksör et al. 2006). These studies were conducted in Finland and Sweden, and 
the prevalence of asthma at the age of 17-20 years was similar, 41-43 %, in both of 
these studies (Piippo-Savolainen et al. 2004, Goksör et al 2006).  
 
 
Lung function 
   In the population-based lung function studies, LRTI in infancy has been associated 
with lowered lung function, as measured by forced expiratory flows, until the age 10-11 
years (Stein et al. 1999b, Håland et al. 2009), and adolescents who had a history of 
wheezing before the age of three years, have had significantly lower forced expiratory 
flows than those with no history of early wheezing (Morgan et al. 2005). However, in 
some studies it was lung function at birth rather than LRTIs in the first years of life 
which has explained the later deficits in lung function (Håland et al. 2009).  
   In the lung function studies after hospitalization for early wheezing, forced expiratory 
flows have been reduced at the age of 10-13 years (Noble et al. 1997, Sigurs et al. 
2005). Increased BHR has been demonstrated to dry-air (Sigurs et al. 2005) or to 
methacholine (Gurwitz et al. 1981, Wennergren et al. 1997).  Abnormal lung function 
parameters, measured by FVS, were seen in 31-36 % of the subjects, compared with 11-
16 % of the controls, in the bronchiolitis cohorts followed-up until adulthood (Piippo-
Savolainen et al. 2004, Goksör et al. 2008).  
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2.3. Early-life predictive factors for long-term outcome after early childhood 
wheezing 
      The question of whether acute virus-induced wheezing in infancy can cause asthma, 
or is only a marker of a predisposition towards asthma has been addressed in many 
studies. Viruses cause direct cytopathic effects to the epithelium, which may evoke 
physiologic changes in the airways. In addition, viruses can interact with both innate 
and adaptive immune responses, and these effects may be different depending on the 
environmental factors and genetic predisposition of the host. The march from early life 
wheezing to persistent asthma is complex and evidently multi-factorial with many host- 
and environmental factors involved in the process.  
 
2.3.1. Age 
   In Tucson's study, 20 % of the children with wheezing only during the first year of 
life, wheezed after the age of three years, with the figures for second and third year 
wheezing being 40 % and 60-70 %, respectively (Taussig et al. 2003).  However, the 
follow-up of the Tucson's cohort has shown that persistent wheezing (from infancy until 
age six) is a risk factor for asthma in adulthood, suggesting that most forms of asthma 
have their origins in early childhood (Stern et al. 2008). An increasing number of 
asthma risk factors become involved already in early life, probably between the ages 
one to two years, which might explain the increasing risk of recurrent wheezing at this 
age (Jartti et al. 2009). However, there are also opposite findings: in infants hospitalized 
for RSV-induced wheezing at age less than 12 months, the occurrence of wheezing 
symptoms was high and persisted up to the teenage years (Sigurs et al. 2005), 
suggesting that severe disease in a very young infant may have a different impact on the 
development of asthma than a milder disease. 
 
2.3.2. Lung function in infancy 
   In the Tucson birth cohort, VmaxFRC levels, measured shortly after birth, was lowest 
in children who wheezed only during the three first years of life but not thereafter 
(Morgan et al. 2005). In addition, wheezing persisting from early childhood up to the 
age of 11 years has been associated, independent of atopy, with reduced VmaxFRC 
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measured in infancy (Turner et al. 2004).  Increased BHR to histamine shortly after 
birth has been related to transient wheezing (Wilson et al. 2004), but when BHR is 
present at the age of 12 months, it is often persistent and associated with the 
development of asthma by the age of 11 years (Turner et al. 2009). Furthermore, there is 
also evidence, that at least in atopic infants, BHR, measured shortly after wheezing in 
infancy, is related to the development of asthma in a ten-year follow-up (Saga et al. 
2001).  
   In clinical practice, a response to bronchodilators is often considered to be a sign of 
asthma. The early bronchodilator response, as evaluated by tidal lung function 
measurements in asymptomatic children with a history of wheezing at less than two 
years of age, was significantly larger than in non-wheezing controls, and the value 
increased with an increasing number of asthma risk factors (Lodrup Carlsen et al. 2004). 
However, unfortunately the early bronchodilator responses with regard to later asthma 
status of the children were not reported in that study. 
 
2.3.3. Viruses 
 
RSV 
    In the Tucson birth cohort, the children with a history of RSV-LRTI, including 
pneumonia cases, during  the first three years of life were more likely to still be having 
episodes of wheezing up to the age of 11 years, but no longer at the age of 13 (Stein et 
al. 1999b). Furthermore, at the age of 11 those children with a history of RSV-LRTI had 
a lower forced expiratory volume in one second (FEV1) and they were more likely to 
respond bronchodilators than children with no history of LRTI in infancy (Stein et al. 
1999).  A history of RSV-LRTI in infancy was unrelated to skin prick-test (SPT) 
positivity at age 11 (Stein et al. 1999b). Similarly, in another birth cohort study, RSV-
bronchiolitis requiring hospitalization at the age less than 12 months was associated 
with asthma, but not with the development of atopy compared to the other population in 
the cohort by the age of seven years (Henderson et al. 2005).  
   There are a limited number of hospital-based long-term follow-up studies examining 
the association between RSV-induced wheezing and asthma. RSV-LRTI requiring 
hospitalization during the first year of life was not associated with asthma in a 
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retrospective study conducted in Northern Finland, and even a reduction in SPT 
positivity was seen at the age of 6-10 years in children with a history of hospitalization 
for RSV-LRTI in infancy when compared to matched controls (Juntti et al. 2003). In a 
prospective Swedish study, hospitalization for RSV bronchiolitis at the age of less than 
12 months was found to be a risk factor for asthma compared to the matched controls at 
the follow-up visits at the ages of three, seven and 13 years. However, a reduction in 
risk ratios was seen with increasing age (Sigurs et al. 1995, 2000 and 2005, Perez-yarza 
et al. 2007), pointing to a disappearance of the effect of early RSV infection. However, 
decreased lung function and increased BHR to dry-air hyperventilation compared to 
matched controls could still be demonstrated at age 13 (Sigurs et al. 2005). Sensitization 
to common allergens was more common in RSV subjects than in matched controls at 
the age of 13 (Sigurs et al. 2005). In a 20-year prospective follow-up, asthma and SPT 
positivity were not more common after RSV bronchiolitis in infancy than than 
corresponding value in controls (Korppi et al. 2004b). However, indices in the FVS, 
FEV1/forced vital capacity (FEV1/FVC) and maximal expiratory flow when 25 % of the 
FVC remains to be expired (MEF25), were lower in subjects with a history of RSV 
bronchiolitis compared to controls (Korppi et al. 2004b). In studies comparing RSV 
bronchiolitis to non-RSV bronchiolitis, no long-term differences in asthma prevalence 
have been observed between the groups (Wennergren et al. 1997) or asthma prevalence 
has been even lower, as seen in the present cohort at an early school age (Kotaniemi-
Syrjänen et al. 2002), and in another bronchiolitis cohort in adolescence (Hyvärinen et 
al. 2005) and in early adulthood (Piippo-Savolainen et al. 2007b). However, there are no 
long-term follow-ups which have used the novel molecular methods available for viral 
diagnoses. 
 
Rhinovirus 
   Many studies have demonstrated that rhinoviruses are the major cause of asthma 
exacerbations in both children and adults (Jartti et al. 2004, Friedlander et al. 2005). 
Impaired innate antiviral responses in asthmatics have been observed (Kelly and Busse 
2008), and persistence of rhinovirus in asthmatic bronchial epithelium, also in infants, 
has been demonstrated (Kelly and Busse, Malmström et al. 2006). It has been postulated 
that rhinovirus plays a role in the pathogenesis of remodelling by generating the 
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mediators involved in the process (Leigh et al. 2008). However, population-based long-
term follow-up-studies on the association between early rhinovirus-induced wheezing 
and subsequent asthma are lacking, since no molecular viral diagnostics were available 
before the 1990s. The Childhood Origins of ASThma cohort, a birth cohort consisting 
of infants with at least one atopic parent,  demonstrated that rhinovirus-induced viral 
wheezing, though not requiring hospitalization, was a significant predictor of asthma at 
the age of six years (Jackson et al. 2008). In another high-risk cohort, wheezing induced 
by rhinovirus either alone or in combination with RSV at less than one year of age was 
associated with wheezing at age five years, but only in children sensitized at less than 
two years of age (Kusel et al. 2007), and these authors concluded that viral infections 
may interact with the onset of atopy in infancy to promote later asthma.   
   Seen in the present cohort at early school age, asthma was more common after 
rhinovirus aetiology of early wheezing compared the situation when the wheezing was 
attributable to RSV or other viral causes (52% vs. 15%) (Kotaniemi-Syrjänen et al. 
2003b), and rhinovirus aetiology associated with early wheezing was linked with BHR 
to exercise (Kotaniemi-Syrjänen et al. 2008). However, there are no long-term follow-
up studies with which to conduct a comparison of the outcomes after rhinovirus and 
RSV-bronchiolitis.   
 
Other viruses 
   Other respiratory viruses causing early wheezing, including probably also the newly 
discovered hMPV and bocavirus, have been included into the non-RSV-group in studies 
which have evaluated the role of viral aetiology of early wheeze on the later respiratory 
morbidity. Hospitalization for hMPV bronchiolitis has been associated with asthma at 
pre-school-age (García-García et al. 2007), but the long-term outcome is unknown. In 
addition, the outcome after bronchiolits caused by bocavirus is unknown. 
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2.3.4. Atopy 
  As presented in Figure 1, the Tucson birth cohort study classified wheezing during the 
first three years of life into transient wheezing, non-atopic persistent wheezing and 
atopic persistent wheezing or asthma based on the development of atopy and the 
persistence of wheezing symptoms by the age of six years (Taussig et al. 2003). 
Transient wheezers are individuals who wheeze only during the first three years of life 
and are not likely to be atopic or to have an atopic predisposition, and in most of these 
children, the wheezing symptoms will have disappeared before school age.  Children 
with non-atopic persistent wheezing may wheeze both during the first three years of life 
and at the age of six years, but the risk of wheezing decreases with age and is no longer 
significant at the age of 11-13 years.  Atopic persistent wheezers are often sensitized to 
inhalant allergens, and the risk of wheezing persists from infancy at least up to early 
adolescence, and this group also shows the lowest level of lung function at the ages six 
and 11 years (Taussig et al. 2003, Morgan et al. 2005).  Thus, an early onset of the 
symptoms and atopic sensitization are believed to be important risk factors for severe 
and persistent disease (Taussig et al. 2003, Morgan et al. 2005).  However, sensitization 
to allergens was not studied before six years of age in the Tucson birth cohort. The 
German Multicenter Allergy Study cohort is the only birth cohort study which has 
evaluated the role of early atopic sensitization, as defined by serum specific IgE (sIgE), 
on wheezing at 11-13 years of age in children with a history of wheezing before three 
years of life. In that study, a positive family history of atopy and early sensitization to 
perennial allergens were the strongest risk factors for persistent wheezing (Matricardi et 
al. 2008). Early sensitization to food allergens predicted the persistence of wheezing in 
the univariate analyses, but no longer in the multivariate analyses (Matricardi et al. 
2008). 
   In the present cohort, early atopic dermatitis and sensitization (defined by serum sIgE) 
to wheat, egg white or inhalant allergens were predictive for asthma at early school age 
(Kotaniemi-Syrjänen et al. 2003a). In the Finnish cohort which was followed up until 
adulthood, parental asthma predicted asthma and parental atopy was associated with 
pathological lung function (Piippo-Savolainen et al. 2004). In addition, early 
sensitization to common inhalant allergens, as measured by non-automated 
radioallergosorbent tests (RAST), predicted asthma until the age of 13.5-16 years 
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(Piippo-Savolainen et al. 2007a). However, there are no other long-term follow-up 
studies after hospitalization for virus-induced wheezing with measurements of serum 
sIgE to common food and inhalant allergens determined in infancy. 
 
2.3.5. Early exposure and sensitization to animal danders 
    In the 2000′s, many studies have documented that early-life exposure to animals can 
decrease the subsequent development of allergy and asthma (Ownby et al. 2002, von 
Mutius et al. 2007). The theory known as the hygiene hypothesis proposed that 
exposure early in life to house dust, animals and livestock increases an infant′s exposure 
to endotoxins or other protective factors originating from the animals or their microbial 
flora (Strachan 1989, Ownby and Johnson 2003, von Mutius et al. 2007). Increase in the 
Th1 immunity leading to increase in IFN- γ production, but not in Th2 interleukins, 
such as IL-4 and IL-13, may be the mechanism to explain why exposure to infective 
agents could reduce the production of sIgE and the prevalence of allergic diseases and 
asthma (von Mutius 2007). In addition to Th1/Th2 balance, T regulatory cells may have 
a central role in controlling immune responses such as the rate of secretion of sIgE from 
the B cells (Akdis et al. 2005, von Mutius 2007). 
   Birth cohort studies on early exposure to furry pets and the later development of 
asthma have given inconsistent results (Apelberg et al. 2001 and Ownby and Johnson 
2003), from an increased wheezing risk in children with asthma in parents (Sandin et al. 
2004) to a decreased asthma risk, at least in low-risk children, continuing until 
adolescence and even longer (Remes et al. 2001). 
   In the German birth cohort,  intense exposure to cat or mite allergens in wheezing 
infants at age less than three years was not associated with wheezing at the age 13 years 
(Matricardi et al. 2008), but sensitization to cat or mite allergens was a strong predictor 
of wheezing (Matricardi et al. 2008).  In the Finnish post-bronchiolitis study, neither 
exposure nor sensitization to cat or dog dander predicted the appearance of asthma in 
early adulthood (Piippo-Savolainen et al. 2007a).  
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2.3.6. Environmental tobacco smoke exposure 
   Exposure to ETS in utero and in infancy reduces lung function and affects lung 
function development (Moshammer et al. 2006, Carlsen et al. 2008, Landau et al. 2008). 
In particular, there is an association between maternal smoking and development of 
asthma in childhood (Cook et al. 1999), and the effect of maternal smoking during 
pregnancy on lung function at school age may be greater than the effect of exposure to 
ETS after birth (Moshammer et al. 2006). There are no long-term follow-up studies 
which have evaluated the role of ETS on the development of asthma after early 
childhood wheezing. In the Tucson birth cohort, maternal smoking during pregnancy 
was linked to low levels of lung function before any LRTI had developed and to the 
transient wheezing phenotype (Stein et al. 1999).  In the German birth cohort, in early 
wheezers, parental smoking was not a risk factor for the persistence of wheezing at 
puberty (Matricardi et al. 2008).  
   In the Swedish long-term follow-up, exposure to ETS at the time of hospitalization for 
virus-induced wheezing in infancy was predictive of asthma at the age of 10 years, and 
both pre- and postnatal exposure to tobacco smoke were independent risk factors for 
asthma in early adulthood, and maternal smoking during pregnancy was an independent 
risk-factor for BHR (Wennergren et al. 1997, Goksör et al. 2007). The authors 
concluded that small airway function in early adulthood may be attributable to by 
prenatal exposure to tobacco smoke, but post-natal exposure to ETS increases the 
asthma risk by increasing the risk of active smoking in early adulthood (Goksör et al. 
2007). In the Finnish post-bronchiolitis study, exposure to maternal smoking at less than 
two years of age was not associated with asthma in early adulthood, but it was a 
significant risk factor for lung function abnormalities at that age (Piippo-Savolainen et 
al. 2006).  
 
2.3.7. Eosinophilic inflammation  
   The role of eosinophilic inflammation is obscure in early childhood wheezing.   It is 
unclear which age is critical for the development of eosinophilic inflammation and the 
appearance of permanent structural changes typical for asthma in the airways of 
wheezing children. In recent bronchial biopsy studies, evidence was found that the age 
from one to three years is probably the most critical period, since changes were not seen 
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even in children with a history of severe wheezing younger than 24 months but the 
changes could be demonstrated in wheezing children by three years of age (Saglani et 
al. 2005, Saglani et al. 2007). In addition, there seems to be a subgroup of RSV-positive 
wheezing infants presenting with airway eosinophilia and increased IL-5 levels and IL-
5/ IFN-γ –ratios, which points to  a heterogeneity of airway inflammation in RSV-
induced wheezing and Th2-type-response in a subgroup of wheezing infants with 
airway eosinophilia (Kim et al. 2003). Furthermore, in a recent study, blood 
eosinophilia was postulated to be an early sign of allergic inflammation, even before 
eosinophilia could be detected in alveolar or bronchial tissue (Just et al. 2008). 
   In the birth cohort studies, blood eosinophilia has been considered as a significant risk 
factor when assessing asthma risk in children with repeated wheezing at less than three 
years of age (Castro-Rodriquez et al. 2000, Guilbert et al. 2004). In addition, lack of 
eosinophilia in infants with a history of recurrent wheezing has been predictive of future 
remission (Just et al. 2008). Blood eosinophilia during hospitalization for RSV 
bronchiolitis at less than 18 months of age has been predictive for wheezing until the 
age of seven (Ehlenfield et al. 2005). Activated eosinophils release a wide spectrum of 
proteins, such as eosinophil cationic protein (ECP). Accordingly, elevated levels of ECP 
in serum and/or the presence of ECP in respiratory secretions have been associated with 
subsequent wheezing and even asthma in infants with RSV bronchiolitis (Pifferi et al. 
2001), and as seen in the present cohort, in young children wheezing with other viruses 
at less than two years of age (Reijonen et al. 1997a and b). However, the role of blood 
eosinophils and ECP in the prediction of persistent asthma has not been established in 
long-term follow-up studies. Neither blood eosinophilia nor elevated serum levels of 
ECP evaluated at less than two years of age were associated with asthma at the age of 
10 years in a Swedish study (Wennergren et al. 1997). Likewise, no association was 
seen between blood eosinophilia during an acute viral wheeze in infancy and later 
asthma in a Finnish bronchiolitis cohort followed-up until adulthood (Piippo-Savolainen 
et al. 2007c). However, the lack of eosinopenic response, i.e. a physiologic decrease in 
blood eosinophil count, to infection and blood eosinophilia when there was no infection 
in infancy were significant risk factors for the development of asthma by the teenage 
years and in adulthood (Hyvarinen et al. 2005 and Piippo-Savolainen et al. 2007c). 
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2.3.8. Neutrophilic inflammation 
   Neutrophil accumulation is more predominant than eosinophil accumulation in airway 
inflammation associated with acute viral wheeze in infancy (Kim et al. 2003, Marguet et 
al. 2008).  MPO is the most abundant protein in neutrophils (Klebanoff et al. 2005), and 
the main function of MPO is to kill bacteria and other pathogens phagocytised by 
neutrophils (Klebanoff et al. 2005). MPO is released from neutrophils also during RSV 
infection (Jaovisidha et al. 1999), and it possesses the capacity of damaging lung 
epithelial cells (Haegens et al. 2008) and in addition, it may have pro-inflammatory 
properties (Lau et al. 2005).  However, the role of neutrophils and their products, such 
as MPO, in asthma and other respiratory disorders has been poorly studied. In adults, 
there is preliminary evidence to suggest that neutrophils from patients with asthma 
release more MPO than do cells from subjects without asthma (Carlson et al. 1991). An 
inverse relationship has been reported between lung function and serum MPO levels in 
patients with allergic asthma (Monteseirin et al. 2001). The results from the studies 
conducted in children suggest that serum MPO levels are higher in children with 
symptomatic or unstable asthma, when compared to children with episodic or non-
symptomatic asthma (Kristjansson et al. 1994, Scher et al. 1996, Carlsen et al. 1997, 
Kalayci et al. 2000), and bacterial infections increase serum MPO levels in both 
asthmatic and non-asthmatic children (Tauber et al. 1999). No association has been 
reported between serum MPO levels and atopy (Boner et al. 1993, Carlsen et al. 1997).  
      No significant differences in serum MPO levels have been found between infants 
with recurrent wheezing and healthy controls, and furthermore, serum MPO showed no 
association with BHR assessed by tidal flow volume responses to inhaled salbutamol 
(Lodrup-Carlsen et al. 1995). There is only one earlier study which has examined the 
role of serum MPO, measured in early-life wheezers, in the prediction of subsequent 
wheezing and later asthma. In that study, serum MPO was increased in infants less than 
12 months old who had been hospitalized for RSV-induced bronchiolitis but the level 
decreased within a  few weeks, but serum MPO at any level was not predictive for 
subsequent wheezing and asthma in the two-year follow-up (Sigurs et al. 1994). 
However, there are no long-term follow-up studies on serum MPO levels in wheezing 
infants and the subsequent risk of developing asthma. 
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2.3.9. Clinical tools for identifying the child at high risk of developing asthma after 
early childhood wheezing 
   Wheezing in infancy is a heterogenic condition. Most of the children with wheezing 
episodes in infancy have normalized by school age, but in some infants, early wheezing 
is the first sign of childhood asthma (Figure 1). At present, there is no laboratory 
marker, biological or genetic, available which can recognize those wheezing infants 
who are at high risk of developing asthma. A combination of clinical characteristics and 
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simple biological markers has been created to form algorithms, which may identify, at 
an early stage of the disease, those wheezing children at a high risk of later asthma 
(Figure 1). The algorithms developed to facilitate the prediction of later asthma in 
wheezing children aged less than three years are presented in Table 4. Castro-Rodriquez 
et al. introduced the first algorithm “asthma predictive index” (API) (Castro-Rodriguez 
et al. 2000), to be applied to predict which subjects who suffer wheezing at less than 
three years of age will have asthma between the ages six and 13 years. The algorithm 
exhibited good specificity of 85-97%, but a low sensitivity of 16-42 % only.  The API 
was later modified (mAPI) for the use in the Prevention of Early Asthma in Kids trial to 
select recurrently wheezing children for secondary asthma prevention with inhaled 
corticosteroids (Guilbert et al. 2004).  In addition to API and mAPI, the algorithms have 
been revised, based on the results of the Finnish and Swedish post-bronchiolitis studies, 
to be more suitable for evaluating infants and toddlers being treated for wheezing in 
hospital (hAPI, Piippo-Savolainen and Korppi 2008). 
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3. AIMS OF THE STUDY 
 
The main aims of this thesis were to evaluate the outcome 11 years after wheezing 
requiring hospitalization in infancy, and in this way to identify at-risk infants, to find 
risk factors present already during wheezing in infancy for teenage asthma and for 
asthma lasting throughout childhood until teenage. 
 
The specific aims of the study were: 
1. To evaluate the prevalence of teenage asthma and the prevalence of persistent childhood 
asthma after hospitalization for wheezing in infancy. 
2. To study which host, viral, and environmental risk factors, present during 
hospitalization for wheezing in infancy, would be associated with teenage asthma and/or 
persistent childhood asthma. 
3. To study whether early exposure to dog and cat allergens would be related to early 
teenage asthma and/or persistent childhood asthma and to sensitization to these 
allergens. 
4. To study whether clinical responses to bronchodilating agents in infancy can be used to 
identify those wheezing children at a high risk of developing later asthma in childhood. 
5. To elucidate whether markers of eosinophilic activation, i.e. elevated blood eosinophil 
count or elevated levels of eosinophil cationic protein in serum or in nasopharyngeal 
aspirate, predict later childhood asthma after hospitalization for wheezing in infancy. 
6. To evaluate the role of neutrophil-derived serum myeloperoxidase, when measured 
durig infancy, in the prediction of subsequent asthma. 
7. To find risk factors, already present during hospitalization for wheezing in infancy, for 
abnormal flow volume spirometry and bronchial hyper-reactivity in the teenage years.   
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4. SUBJECTS AND METHODS  
 
 
4.1. Enrolment and acute-phase study 
4.1.2 Study subjects 
  Between January 1st 1992 and November 2nd 1993, 100 consecutive children, aged 1-
23 months, were recruited into this study using the inclusion criteria of respiratory 
infection-related wheezing (the index episode of wheezing) and respiratory distress 
requiring inpatient treatment in the Department of Paediatrics, Kuopio University 
Hospital, Finland (Reijonen et al. 1995). Patients were excluded if they had a history of 
chronic cardiorespiratory disease, including asthma, or if they received regular 
medication for any pulmonary disease, or if they had taken bronchodilators in the 
preceding six hours, or if acute respiratory failure was threatening (Reijonen et al. 
1995). 
 
4.1.3. Outcome measures and acute-phase intervention study 
    In all infants, a baseline clinical evaluation was performed, consisting of 
measurements of respiratory rate, heart rate (Component Central Monitor, Hewlett 
Packard GMBH, Böblingen, Germany), oxygen saturation (Ohmeda Biox 3700e Pulse 
Oximeter, Ohmeda, Louisille, Columbia), body temperature (°C, rectally) and clinical 
assessment of Respiratory Distress Assessment Instrument (RDAI) score (Reijonen et 
al. 1995). The RDAI score, assessed by one of the four study doctors, was based on two 
respiratory variables, wheezing and retractions (Lowell et al. 1987).  
   In order to investigate whether racemic epinephrine (adrenaline) and/or albuterol 
(salbutamol) would improve the clinical condition of infants, patients were randomly 
assigned to one of four treatment groups. To prevent confounding by viral aetiology and 
wheezing history, the randomisation was performed in clusters of 12 cases,  and the 13 
children with and the 87 children without any previous history of wheezing were 
randomised separately (Kernan et al. 1999). 
   The crossover study design is presented in Table 5. The REP (racemic epinephrine 
followed by placebo) group first received nebulized racemic epinephrine, and the AP 
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(albuterol followed by placebo) group first received nebulized albuterol; both groups 
received nebulized physiological saline (0.9% sodium chloride) solution 30 minutes 
later. The PRE (placebo followed by racemic epinephrine) and the PA (placebo 
followed by albuterol) groups first received physiological saline, and 30 minutes later 
either racemic epinephrine (PRE) or albuterol (AP).  
   Racemic epinephrine was given at a dose of 0.9 mg/kg (Micronefrin, Bird Products 
Corp, Palm Springs, California), and albuterol (Salbuvent, Orion Pharma, Espoo, 
Finland) was given at a dose of 0.15 mg/kg. Solutions were added to 2 ml of 
physiological saline solution. All inhalations were administered by a trained nurse using 
a Spira Module 2 Nebulizer (Respiratory care Center, Hämeenlinna, Finland) with a 
continuous 5-L/min flow of 100% of oxygen. The design of the administration of the 
drugs was double-blind; neither the patients or their parents, nor the study doctors knew 
which drug (or placebo) was being administered. 
   The clinical assessment of oxygen saturation, respiratory rate, heart rate and RDAI 
score was repeated, by the same study doctor as at the baseline assessment, 15 and 30 
minutes after each inhalation (Reijonen et al. 1995). Sixty minutes after the first 
inhalation, intramuscular administration of epinephrine (0.01mg/kg) was given to all 
patients (Reijonen et al. 1995).  
 
Table 5. The crossover study design of the acute-phase intervention study 
Periods Period 1 Period 2 
Clinical 
evaluations 0 min 15 min 30 min 45 min 60 min 
REP a n=24 RE   P   i.m. epinephrine 
AP b n=27 A P i.m. epinephrine 
PRE c n=24 P RE i.m. epinephrine 
PAd n=25 P   A   i.m. epinephrine 
a Racemic epinephrine (RE) followed by placebo (P) 
b Albuterol (A) followed by P 
c Placebo (P) followed by racemic epinephrine (RE) 
d Placebo (P) followed by albuterol (A) 
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4.1.4. Baseline data 
   The baseline and family data were collected by interviewing the parents during the 
hospitalization by using a structured questionnaire including questions on the history of 
wheezing and atopic dermatitis, as well as on the family history of asthma and atopic 
diseases. Only diagnoses made by a physician were accepted. In addition, information on 
maternal smoking during pregnancy and early exposure to ETS and pets at home or at day 
care in infancy was recorded (Reijonen et al. 1995 and 1996).  
 
4.1.5. Laboratory studies 
 
Determination of blood eosinophils, serum eosinophil cationic protein and serum total 
immunoglobulin E  
    A venous blood sample was drawn from each patient within the 24 hours after 
admission for the determination of blood eosinophils (B-EOS), serum eosinohil cationic 
protein (S-ECP) and serum total IgE. B-EOS were counted by using an automated cell 
counter (Coulter Counter STKS, Coulter Electronics, Hialeah, FL) and expressed as 
cells x109 /L (Reijonen et al. 1997a).  S-ECP was determined according to the 
instructions of the manufacturer (Pharmacia ECP RIA, Pharmacia, Uppsala, Sweden), 
as described earlier in detail (Reijonen et al. 1997a). The cut-off limits for the elevated 
values applied in the later studies were 0.450 cells x 109/L for B-EOS (Eisen 1980, 
Reijonen et al. 1997a, Kotaniemi-Syrjänen et al. 2002, Simon et al. 2007), 16.0 µg/L or 
20.0 µg/L for S-ECP (Peterson et al. 1991, Koh et al. 2007) and 60 kU/l (144 µg/l) for 
serum total IgE (Saarinen et al. 1982). 
 
Determination of nasopharyngeal eosinophil cationic protein  
   NPA samples, obtained within 24 hours after hospital admission, were taken by 
placing a catheter into the nasopharynx, followed by aspiration into a mucus trap 
(Reijonen et al. 1997b). Each sample was stored frozen in a tightly capped tube at -70 
°C until processed within four months.  After thawing and weighing, the sample was 
suspended in 2-5 ml of ice-cold 0.9% NaCl solution to produce a homogenous 
suspension and then centrifuged for 10 min (1.400g), and the precipitate was discarded 
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(Reijonen et al. 1997b). The ECP concentration in the supernatant was determined 
according to the instructions of the manufacturer (Pharmacia ECP RIA, Pharmacia, 
Uppsala, Sweden). ECP was expressed as nanograms (ng)/g of NPA (ECP-NPA) after 
correction for dilution with 0.9 % NaCl (Reijonen et al. 1997b). The receiver operating 
characteristic (ROC) curve analysis was applied to find the cut-off concentration for 
NPA-ECP which would maximize true positive cases (sensitivity) and minimize false 
positive cases (1-specificity). The ROC analyses were performed in relation to both 
asthma at the median age of 12.3 years (teenage asthma) and persistent childhood 
asthma (PCA), and the best cut-off limit for NPA-ECP was 815.0 ng/g with relation to 
both teenage asthma (sensitivity 0.42, specificity 0.83, positive likelihood ratio (LR+) 
2.5) and with relation to PCA (sensitivity 0.58, specificity 0.83, LR+ 3.4).  
 
Determinations of serum myeloperoxidase  
   The level of serum myeloperoxidase (MPO) was determined in frozen serum samples 
obtained on admission (Measurement 1; S-MPO1) by radioimmunoassay (MPO RIA, 
Pharmacia AB, Uppsala, Sweden), and the concentrations were expressed as 
micrograms (µg)/L. The total variation of the method was 5,8 - 12,3 % in the 
concentration range of 32 - 730 ug/L. S-MPO measurements were repeated by the same 
method 6 weeks (measurement 2; S-MPO2), 4 months (measurement 3; S-MPO3) and 
12 months (measurement 4; S-MPO4) later at the median ages of 0.98 years (range 
0.20-2.10), 1.15 years (0.39-2.26) and 1.86 years (1.14-3.12), respectively. 
 
Determination of serum allergen -specific IgE antibodies 
    In 2000, serum specific IgE (sIgE) antibodies (Phadiatop Combi®) were determined 
in frozen serum samples, which had been obtained during the index episode of 
wheezing in 1992-1993, by fluoroenzyme-immunometric assay (FEIA), UniCAP™ 
(Pharmacia, Uppsala, Sweden) (Paganelli et al. 1998). The presence of serum sIgE 
antibodies in response to the mixtures of inhalant and food allergens was screened first 
by the detection limit (≥0.35 kU/l), and if positive, serum sIgE antibodies were 
measured, with the same limit.  Phadiatop combi® panel for food allergens included 
egg white, cow's milk, fish, wheat, peanut, and soy bean, and for inhalant allergens 
timothy grass pollen, birch pollen and mugwort pollens, cat dander, dog dander, horse 
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dander, house dust mite D.  pteronyssinus, and spores of the mould C. herbarum. 
 
Viral studies 
   Viral infections were studied by antigen detection in the NPAs taken at entry and by 
antibody measurements in paired sera. Direct detection of viral antigens by time-
resolved fluoroimmunoassay (TR-FIA) was available for RSV, parainfluenzaviruses 1-
3, influenza A and B viruses, and adenoviruses (Reijonen et al. 1998). Serology by CF 
was studied for the same respiratory viruses in paired sera taken six weeks apart: four-
fold or greater increase in titres was defined as a positive result (Reijonen et al. 1997b).  
    In 2000, 81 frozen good-quality NPA samples taken on admission in 1992-1993, 
were evaluated available for RT-PCR for detection of rhinoviruses, enteroviruses and 
coronaviruses (strains 229E and OC-43) (Kotaniemi-Syrjänen et al. 2003b). In 2002, an 
adequate NPA sample was available for the detection of the RSV genome by RT-PCR 
in 61 cases (Kotaniemi-Syrjänen et al. 2005). 
 
4.2. Intervention with anti-inflammatory medication and short-term follow-up 
   Nebulized anti-inflammatory therapy was randomly given for 16 weeks from 
admission: 34 patients received cromolyn sodium, 34 received budesonide, and 32 
control patients received no anti-inflammatory medication (Reijonen et al. 1996). For 
the first eight weeks, 20 mg of cromolyn sodium was given four times a day and 500 µg 
of budesonide twice a day. For the second eight weeks, the doses were reduced to 20 mg 
of cromolyn sodium three times a day and 250 µg of budesonide twice a day (Reijonen 
et al. 1996). 
   After the index episode of wheezing, several study visits were organized in order to 
follow-up the respiratory status and allergic manifestations of the children. SPTs were 
studied for the first time eight months after the hospitalization at the median age of 1.5 
years. A trained nurse performed the tests by using the ALK SPT extracts including cat 
and dog epithelial dander allergens (ALK Laboratories, Copenhagen, Denmark).  
   Three years after the index episode of wheezing, at the median age of 4.0 years (range 
3.2-5.1 years), 89/100 children attended the pre-school follow-up visit (Reijonen et al. 
2000). Children who were either on continuous anti-inflammatory medication for 
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asthma or had suffered from at least two doctor-diagnosed wheezing episodes after the 
index episode of wheezing were considered to have asthma (Reijonen et al. 2000). 
 
4.3. Follow-up visit at early school age 
   In 1999, at a median 6.3 years (range 5.3-7.2 years) after the index episode of 
wheezing 82/100 children attended the follow-up visit at a median age of 7.2 years 
(range 5.8-8.8 years). Symptoms suggestive of asthma and allergies were recorded and 
the baseline pulmonary function was examined by FVS (Medikro, Kuopio, Finland). 
The FVS was followed by the exercise challenge test (ECT) (Kotaniemi-Syrjänen et al. 
2002), which consisted of 8-minute free running outdoors at the heart rate of ≥ 80% of 
maximum.  The ECT was considered as positive if there was auscultatory wheezing 
present after the exercise and/or a 15 % or greater fall in FEV1 compared to baseline 
value (Kotaniemi-Syrjänen et al. 2002). Asthma was considered to be present if 1) the 
child had suffered from at least two episodes of wheezing and/or prolonged cough apart 
from infection for at least four weeks during the preceding 12 months and the exercise 
challenge test was pathological or 2) the child was on continuous inhaled anti-
inflammatory medication for asthma (Kotaniemi-Syrjänen et al. 2002). 
 
4.4. Follow-up visit at early teenage 
4.4.1. Study subjects  
   In 2004, from January to March, 81/100 children, 21 girls and 60 boys, attended the 
clinical follow-up visit in the Department of Paediatrics, Kuopio University Hospital, 
Finland. The median follow-up time from the index episode of wheezing was 11.4 years 
(range 10.3-12.2) and the median age at the follow-up visit was 12.3 years (range 10.9-
13.7).  
 
4.4.2. Follow-up data and clinical examination 
   Before the study visit in 2004, a structured questionnaire was sent to the study 
subjects.  Symptoms suggestive of asthma associated with exercise, infections and 
allergens were recorded. The study doctor (Mari Hyvärinen) checked the answers by 
interviewing the children and their parents during the clinical study. In addition to 
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asthma symptoms, the symptoms suggestive of allergic rhinitis, conjunctivitis and 
atopic dermatitis occurring during the preceding 12 months were recorded, and if 
present classified as current. In addition, the ongoing asthma medication was registered. 
   Skin prick tests (SPT) were performed, and the allergens (ALK SPT extracts, ALK 
Laboratories, Copenhagen, Denmark) tested were the outdoor allergens birch, common 
alder and mugwort pollens, pollens of meadow fescue and timothy grass, and spores of 
C. herbarum, and the indoor allergens cat, dog, horse and cow epithelial danders and 
home dust mites D. pteronyssinus and D. farinae and spores of the mold Alternaria 
alternata. The concentrations of standardized allergen extracts were 10 histamine 
equivalent points except for cow (1/100 w/v), C. herbarum (1/20 w/v) and A. alternata 
(100 BU/ml) extracts. Histamine hydrochloride (10 mg/ml) was used as a positive 
control and 50 % glycerol as a negative control. Wheals with a mean (half of the sum of 
the largest diameter and its perpendicular measurement) diameter of at least 3 mm were 
regarded as positive. No reactions were allowed to negative controls.   
 
4.4.3. Studies on lung function and BHR 
 
Baseline lung function 
   Baseline flow-volume spirometry (FVS) was examined by a pneumotachographic 
spirometer (Medikro, Kuopio, Finland). Before the visit, the children were instructed 
not to use inhaled long-acting β2-agonists for 48-72 hours or short-acting β2-agonists 
for 12 hours before the lung function studies.  In addition, no symptoms suggestive of 
respiratory tract infections were allowed. First, the children were carefully instructed on 
how to perform the test. Thereafter, the measurements were repeated three times, and 
accepted if the variation in FEV1 was less than 5 % and the graphic curves were 
appropriate and equal in shape. The FVS was appropriately performed by 80/81 
children. Lung function parameters were expressed as percentages of the gender-
specific and height-related reference values (% of predicted) for Finnish children 
(Salorinne 1989). The parameters registered were FVC, FEV1,  FEV1/FVC, MEF50 
(maximal expiratory flow at 50 % of FVC) and MEF25. From the acceptable FVS 
curves, the best FVC and FEV1 were recorded for further analyses. The other flow-
volume parameters were obtained from three technically satisfactory FVS curves by the 
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envelope method, in which the best superimposed curves from total lung capacity were 
applied to form a composite maximal curve (Quanjer et al. 1993). The cut-off limits for 
abnormal results were < 80 % for FEV1, < 88 % for FEV1/FVC, < 62 % for MEF50 and 
< 48 % for MEF25 (Viljanen 1982). 
 
Tests of BHR 
   The baseline FVS was followed by ECT that consisted of 8-minute free running 
outdoors at the heart rate of ≥ 80 % of the predicted maximum. During running, the 
heart rate was monitored by telemetry (Polar Sport Tester, Polar Elektro Ltd, Kempele, 
Finland) at 1-minute intervals. FVS was measured 5, 10 and 15 minutes after the 
exercise. The FEV1 obtained from the baseline FVS was used in later comparisons.  
FEV1 changes were calculated as follows: [(pre-exercise FEV1 – post-exercise FEV1) / 
pre-exercise FEV1] x 100 %. The ECT was regarded as positive if there was a 10 % or 
greater fall in FEV1 values at 5, 10 or 15 minutes after the running (Godfrey 2000). One 
of the study doctors (Mari Hyvärinen) was responsible for both the performance FVS 
and ECT and the interpretation of the results. The ECT was appropriately performed by 
78/81 children. 
   The methacholine inhalation challenge (MIC) test was performed on a separate day 
from the other lung function studies. The children were given instructions and the 
baseline FVS was performed as described above. Methacholine was inhaled from a 
Spira Electro-2 dosimeter (Spira Respiratory Care Center Ltd, Hämeenlinna, Finland) 
allowing the calculation of the total amount of methacholine inhaled by each subject. 
First, FVS was performed before and after an inhalation of physiological saline, to 
obtain the baseline FEV1. Then, methacholine was inhaled, and the numbers of breaths 
required to achieve a cumulative dose of 20, 80, 300, 900, 2900 and 4900 µg of 
methacholine were 1, 3, 11, 3, 10 and 10, respectively. The concentration of 
methacholine increased from 2.5 mg/ml to 25 mg/ml after the cumulative dose of 300 
µg. The baseline FEV1 value was applied in the comparisons with the measurements 
done 1.5 minutes after each methacholine dose. The test was continued until a 20 % fall 
in FEV1, or until a cumulative dose of 4900 µg of methacholine was reached. The exact 
cumulative dose causing 20 % fall in FEV1 was determined by semilogarithmic 
interpolation and termed the provocative dose (PD20). The methodology of the MIC was 
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the same as that routinely used in our clinic (Pöysä et al. 1992). The MIC test was 
appropriately performed by 69/81 children. 
 
4.4.4. Asthma definition 
   Asthma at the median age of 12.3 years (teenage asthma) was considered to be present 
if 1) the child was on a continuous maintenance or intermittent anti-inflammatory 
medication for asthma or if 2) she/he had suffered from repeated (≥2) episodes of 
wheezing or prolonged (≥4 weeks) cough apart from infections during the preceding 12 
months as reported by parents, and the ECT was regarded as positive. 
   Children, who were regarded to have asthma at all the three follow-up visits, at the 
median ages of 4.0 (Reijonen et al. 2000), 7.2 (Kotaniemi-Syrjänen et al. 2002) and 12.3 
(present study) years, were considered to have persistent childhood asthma (PCA). 
 
4.5. Ethics 
   The study was approved by the Research Ethics Committee of Kuopio University and 
Kuopio University Hospital. Informed written consent was obtained from the children 
and from the parents of the children. 
 
4.6. Statistical analyses 
   The data were analyzed using SPSS 11.5-16.0 software (SPSS Inc.Chicago, IL, USA).  
In univariate analyses, Pearson's Chi square test and Fisher's exact test were used for 
dichotomous data. Fisher's exact test was used when the expected frequency for any cell 
was < 5. The risks are expressed as odds ratios (OR) and their 95% confidence intervals 
(95% CI). Continuous data were analyzed by the independent sample T-test or Mann-
Whitney U-test.      
      The logistic regression was used to calculate the adjusted ORs (aOR) and related 
95% CIs. Analysis of variance (ANOVA) was applied to assess the significance of the 
differences in the continuous baseline FVS parameters (percentages of the gender-
specific height-related reference values) between children with and without a certain 
risk factor present. Each risk factor was analyzed separately. In this model, covariates 
acted as effect modifiers with a bilateral interaction with the risk factor. The association 
between S-MPO1 and oxygen saturation, heart rate, respiratory rate, body temperature 
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and RDAI score on admission as well as the length of hospital stay (in days), was 
studied by linear regression adjusted for age (in months) on admission. The skewed 
MPO data were logarithmically (log10) transformed (LogMPO1). Each variable was 
entered into the age-adjusted linear model separately with LogMPO1 as a dependent 
variable. 
    Repeated measures analyses of variance (ANOVA) was applied to study whether the 
change in LogMPO concentration was significant at a various time points (within-
subject effect), and whether there were any differences in the change between 
intervention groups or later asthma groups (between-subject effects). Separate analyses 
were performed for each group, and the analyses between asthma groups were adjusted 
for age on admission (<12 months/ ≥12 months), atopic dermatitis in infancy and RSV 
aetiology of early wheezing, which have associated with asthma in the earlier studies in 
this cohort (Reijonen et al. 2000, Kotaniemi-Syrjänen et al. 2002). 
   The initial response to acute treatment with regard to later asthma was analysed as a 
crossover study using mixed models (Brown and Prescott 2001). The pooled responses 
used as dependent variables were the mean values of respiratory rates, heart rates, 
oxygen saturations and RDAI scores after the first (mean of the 15 and 30 minute 
assessments of responses, period 1) and second (mean of the 45 and 60 minute 
assessments of the responses, period 2) administration of racemic epinephrine, albuterol 
or placebo. The standard elements of a cross-over trial, such as the period (1 or 2), 
sequence (whether the drug or placebo was given first), treatment (racemic epinephrine, 
albuterol, or placebo) and the random effect of the patient (describing the natural 
heterogeneity of individuals and accounting for the dependence of repeated measures 
from the same subject) were included into the model. In addition, PCA and the 
interaction of PCA and treatment were also included into the model in order to address 
the study hypothesis.  Analyses were performed separately applying either15- and 45-
minute (15 minutes after inhalations) or 30- and 60-minute (30 minutes after 
inhalations) responses as dependent variables. 
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5. RESULTS 
 
 
5.1. Outcomes in the 11-year follow-up 
5.1.1. Prevalence of teenage asthma and persistent childhood asthma (I) 
   Teenage asthma was considered to be present in 32 (40 %) children, and 29 of them 
were on inhaled anti-inflammatory asthma medication; 17 were using inhaled steroids 
and one cromones as continuous medication, and 11 used inhaled steroids intermittently 
during the pollen season and/or infections. The other three children with asthma had 
suffered from repeated wheezing, and as an objective asthma criterion, displayed a 
diagnostic fall in FEV1 (range 12 -31 %) in the ECT. Even though they were taking anti-
inflammatory asthma medication, 22/29 (76 %) children had suffered from repeated 
wheezing episodes or prolonged cough apart from infection during the preceding 12 
months or had a pathological result in the ECT. The asthma criteria were not fulfilled in 
6/31 (19%) children who reported some kind of wheezing and in 5/27 (19%) of those 
who reported repeated wheezing during the preceding 12 months. 
   PCA was present in 20/81 (25%) children, and 27 (33%) children had not had an 
asthma diagnosis between the ages of 4-12 years. As seen in Figure 1, pre-school 
asthma had remitted by school-age in 14/45 (31%) children but relapsed again in 7/49 
(14%) children at teenage. Only 7/33 (21%) children with asthma at school age had 
experienced a remittance by teenage, and whereas, 22/33 (67%) continued to have 
asthma (Figure 2).   
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5.1.2. Prevalence of atopy (I) 
      Allergic rhinitis and/or conjunctivitis was present in 30/81 (37%) and atopic 
dermatitis in 26/81 (32%) children. SPTs were performed in all 81 cases, but one child 
was excluded from the analyses because of a positive reaction to the negative control, 
and 50/80 (63%) children displayed at least one positive reaction. The figures for indoor 
and outdoor allergens were 40/80 (50%) and 42/80 (53%), respectively.  
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   Allergic rhinitis, conjunctivitis and SPT positivity were more common in children 
with teenage asthma and in children with PCA compared to children with no teenage 
asthma or no PCA (Table 6). Atopic dermatitis was more common in children with PCA 
compared to children without PCA, but not in children with teenage asthma compared 
to children with no asthma at that age (Table 6). 
 
Table 6. Atopic manifestations in children with teenage asthma and in children with PCA. 
  
Teenage asthma  PCA 
Atopic manifestations Yes  No  OR a     Yes  No  OR a     
  (n=32) (n=49) (95% CI) n=(20) (n=61) (95% CI) 
Allergic rhinitis n(%) 19(59) 8(16) 7.49 14(70) 13(21) 8.62   
(2.66-21.09) (2.77-26.83) 
Allergic conjunctivitis, n(%) 14(44) 5(10) 6.84 8(40) 11(18) 3.03 
(2.15-21.81) (1.00-9.17) 
Atopic dermatitis, n(%) 14(44) 12(24) 2.40    11(55) 15(25) 3.75     
(0.92-6.23) (1.30-10.78) 
SPTsb:       
At least one positive   
reaction, n(%) 28(90) 22(45) 11.46      18(95) 32(52) 16.31     
(3.07-42.75) (2.05-129.98) 
to indoor allergensc, n(%) 
24(77) 16(33) 7.07    17(89) 23(38) 14.04    
(2.52-19.85) (2.97-66.43) 
to outdoor allergensd, n(%) 
24(77) 18(37) 5.91      15(79) 27(44) 4.72     
      (2.12-16.42)     (1.40-15.89)    
a Non-adjusted analyses. 
b SPTs were available in 80 children (31 with current asthma and 19 with PCA). 
c There were 31 positive reactions to cat, 29 to dog, 20 to horse and 11 to cow's epithelial dander, and 12 
were positive to D.pteronyssinus and 6 to D. farinae. 
d There were 24 positive reactions to birch, 25 to common alder, 34 to meadow fescue, 35 to timothy grass, 
to  3 to mugwort pollen and 4 were positive to C. herbarum. 
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5.1.3. Lung function and bronchial hyper-reactivity (III)  
 
Baseline flow volume spirometry 
   The FVS was appropriately performed by 80/81 (99 %) children (Table 7). On 
average, all parameters were within normal limits when compared to gender-specific 
and height-related references. Children with asthma at early school age and PCA had 
higher FVC than children with no teenage asthma or no PCA, and FEV1/FVC values 
were lower in children with teenage asthma compared to children with no asthma at that 
age (Table 7). In the supplememtary analyses, in which only children without asthma at 
any time formed the non-PCA group, FEV1/FVC values were significantly lower in the 
PCA group than in the non-PCA-group. 
   Twenty-six (33 %) children exhibited an abnormal value in one or more of the four 
FVS parameters. The figure for teenage asthma was 11/32 (34 % vs. 31 % in those with 
no teenage asthma, OR 1.2, 95% CI 0.45-2.98) and for PCA 6/20 (30 % vs. 33 % in 
those with no PCA, OR 0.86, 95% CI 0.29-2.57). Among FVS parameters, children 
with teenage asthma had more often a pathological finding in MEF25 (8/32, 25%) 
compared to children with no asthma at that age (3/48, 6%, OR 5.0, 95%CI 1.21-20.61), 
but children with and without PCA did not differ in terms of any of the FVS parameters 
(data not shown). The three medication groups, i.e. continuous, intermittent and no anti-
inflammatory medication groups differed significantly only in terms of the abnormal 
MEF25 value, the group with continuous medication having higher numbers for 
pathological values than those not taking any medication.  
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Table 7. Baseline lung function by FVS (% of predicted) in all teenage children and in 
children with asthma at that age (teenage asthma) and PCA.  
Parameters in FVS  
All  
Teenage 
asthma PCA 
n=80  n=32 n=20 
FVC, mean 97.79   101.19 a 102.93 c 
(95% CI) (95.04-100.55) (96.08-106.30) (96.74-109.12) 
FEV1, mean 92.23 93.15 95.17 
(95% CI) (89.35-95.12) (87.55-98.76) (88.05-102.30) 
FEV1/FVC, mean  94.55 92.22 b 92.59 
(95% CI) (92.67-96.43) (88.70-95.75) (87.84-97.34) 
MEF50 , mean 81.43 78.12 80.29 
(95% CI) (77.20-85.67) (70.22-86.01) (69.84-90-73) 
MEF25 , mean 71.68 67.57 70.02 
(95% CI) (67.10-76.27) (59.12-76.02) (59.10-80.95) 
a FVC= 95.53 in non-asthmatics (p=0.044 compared to children with asthma at early teenage) 
b FEV1/FVC=96.09 in non-asthmatics (p=0.044 compared to children with asthma at early 
teenage) 
c FVC=96.08 in children with no PCA (p=0.031 compared to children with PCA) 
P-values determined by independent sample t-test. 
 
 Tests of bronchial hyper-reactivity 
   The ECT was appropriately performed by 78/81 (96%) children, and 21 (27%) 
children had a pathological (≥ 10 % fall in FEV1) result. Children with continuous or 
intermittent anti-inflammatory medication had more often a pathological result in the 
ECT (range 11-34 %) compared to those not taking medication (13/27, 48%, vs. 8/51, 
16%, OR 4.99, 95%CI 1.72-14.51).  
   In the MIC test, some kind of BHR (PD20≤4900 μg) was demonstrated in 41 (59 %), 
intermediate to high BHR (PD20≤1600 μg) in 32 (46%), and high BHR (PD20≤400 μg) 
in 11 (16 %) children. As shown in Table 8, children with intermittent or continuous 
anti-inflammatory medication displayed more often a BHR to methacholine at all three 
levels compared to the children with no anti-inflammatory medication.  Likewise, BHR 
to methacholine at all three levels was more common among children with teenage 
asthma or PCA compared to children with no asthma at that age or PCA. The only 
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exception was the BHR to methacholine when one compared children with PCA to 
those without PCA (Table 9). 
   Both the MIC test and the ECT were appropriately performed by 66 children, and 15 
of them had a positive result in both tests (≥10 % fall in FEV1 in the ECT and 
PD20≤1600 μg in the MIC test). Sixteen children were positive in the MIC test alone 
and only three in the ECT alone. 
 
Table 8. BHR to methacholine by consumption of anti-inflammatory asthma 
medication in teenage years. 
  
Intermittent or continuous anti-
inflammatory medication 
BHR to methacholine Yes 
a No  ORb       
n=69 (n=24) (n=45) (95% CI) 
Any, n (%)  
19 (79) 22 (49) 
PD20≤4900μg 
3.97 
(1.26-12.49) 
Intermediate to high, n (%) 
16 (67) 16 (36) 
PD20≤1600μg 
3.63 
(1.27-10.31) 
High, n (%) 
7 (29) 4 (9) 
PD20≤400μg 
4.22 
(1.09-16.32) 
a Intermittent anti-inflammatory medication in 10 and continuous medication in 14 
children. 
b Non-adjusted analyses 
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Table 9. BHR to methacholine according to the presence of teenage asthma and PCA. 
  
Teenage asthma PCA 
BHR to methacholine Yes  No  OR a       Yes  No  OR  a       
n=69 (n=27) (n=42) (95% CI) n=(17) (n=52) (95% CI) 
Any, n (%)  
22 (81) 19 (45) 
5.33 
14 (82) 27 (52) 
PD20≤4900μg 
4.32 
(1.69-16.75) (1.11-16.84) 
Intermediate to high, n (%) 
19 (70) 13 (31) 
5.30 
12 (71) 20 (38) 
PD20≤1600μg 
3.84 
(1.85-15.20) (1.18-12.54) 
High, n (%) 
9 (33) 2 (5) 
10.00 
5 (29) 6 (12) 
PD20≤400μg 
3.19 
(1.20-51.04) (0.83-12.28) 
a Non-adjusted analyses 
 
 
 
5.2. Early-life predictive factors for asthma in the 11-year follow-up (I, II, IV, V, 
VI) 
5.2.1. Age, gender and history of earlier episodes of wheezing (I) 
      Children with teenage asthma had been significantly older on admission than 
children with no asthma at that age (median age 12.02 months vs. 8.77, p=0.033). The 
respective figures for children with and without PCA were 13.75 vs. 9.46 months 
(p=0.002). Teenage asthma was present in 16/52 (31%), and PCA in 7/52 (13%) of 
those hospitalized at less than 12 months of age with the respective figures being 55% 
(OR 2.76, 95% CI 1.08-7.09) and 45% (OR 5.22, 95% CI 1.77-15.40) for those who 
were hospitalized when they were older than 12 months. Gender was not significantly 
associated with teenage asthma or PCA; 8/21 (38%) of females had teenage and 5/21 
(23 %) had PCA, the respective figures for males were 24/60 (40%) and 15/60 (25 %). 
A history of earlier physician-diagnosed wheezing was more common among children 
with teenage asthma or PCA compared to children with no teenage asthma (7/32, 22% 
vs. 3/49, 6%, aOR 3.73, 95% CI 0.87-16.04) or PCA (5/20, 25% vs. 5/61, 8%, aOR 
3.16, 95% CI 0.76-13.10). However, in the age- and sex-adjusted logistic regression, 
these differences were not significant. 
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5.2.2. Family history of asthma and atopy and environmental factors (I, IV) 
   A parental and maternal history of asthma were at least twice  as common in children 
with teenage asthma and in children with PCA in comparison with the children without 
these conditions, but the differences were not statistically significant in the adjusted 
analyses (Table 10). Likewise, no significant differences were seen between parental 
atopy, exposure to ETS or maternal smoking during pregnancy and teenage asthma or 
with PCA (Table 10), and there were no associations between paternal asthma, maternal 
atopy, paternal atopy, paternal smoking or maternal smoking and teenage asthma or 
PCA (data not shown). 
   Early exposure to cats or dogs seemed to be associated with some reductions in the 
risk of teenage asthma or PCA (Table 10). In addition, only 2/12 (17%) children 
exposed to cat and 3/18 (17%) children exposed to dog during infancy had a positive 
SPT reaction to the respective allergens in their teens compared to 29/68 (43%) and 
26/62 (42%) for non-exposed children. These inverse relationships between early 
exposure and later sensitization to cat or dog were not statistically significant after 
adjustment for the presence of atopic dermatitis in children or atopy in parents between 
children with or without teenage asthma (aOR 0.30, 95% CI 0.06-1.57) or between 
children with or without PCA (aOR 0.35, 95% CI 0.09-1.38). In addition, only 3/22 
(14%) of the families with atopic dermatitis in children vs. 19/59 (32%, p=0.095) with 
no atopic dermatitis in children, and 7/38 (18%) with asthma or allergy in parents vs. 
15/43 (35%, p=0.096) with no asthma or allergy, had a dog or cat at home at the time of 
admission.  
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Table 10. Early family and environmental factors in relationship to teenage asthma and PCA. 
Family and environmetnal 
factors 
Teenage asthma PCA 
Yes  No  aORd       Yes  No  aORc        
(n=32) (n=49) (95% CI) n=(20) (n=61) (95% CI) 
Parental history of asthma a, 
n(%) 
8 (25) 5 (10) 3.355 5 (25) 8 (13) 2.74 
(0.92-12.24) (0.67-11.24) 
Maternal history of asthma a, 
n(%) 
5 (16) 2 (4) 5.08 3 (15) 4 (7) 3.22 
(0.87-29.65) (0.56-18.49) 
Parental history of atopy b, 
n(%) 
15 (47) 21 (43) 1.17 9 (45) 27 (44) 1.02 
(0.47-2.95) (0.35-3.03) 
Exposure to ETS during 
infancy, n(%) 
15 (47) 22 (45) 1.35 11 (55) 26 (43) 3.19 
(0.52-3.51) (0.93-10.92) 
Maternal smoking during 
pregnancy, n(%) 
9 (28) 8 (16) 2.02 5 (25) 12 (20) 1.62 
(0.68-6.05) (0.45-5.75) 
Exposure to cat during 
infancy, n(%) 
2 (6) 10 (20) 0.30d 1 (5) 11 (18) 0.34d 
(0.05-1.61) (0.04-3.20) 
Exposure to dog during 
infancy, n(%) 
6 (19) 12 (24) 1.21d  1 (5) 17 (28) 0.235d 
    (0.35-4.16)     (0.03-2.09) 
a Diagnosed by a physician 
b Atopic dermatitis or allergic rhinitis diagnosed by a physician 
c Logistic regression adjusted for sex and age (in months) on admission. After adjustment for RSV-aetiology 
of the index episode of wheezing, the results remained the same.  
d Logistic regression adjusted for age (in months), atopic dermatitis in infants, parental history of asthma 
and RSV aetiology of the index episode of wheezing on admission.  
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5.2.3. Viruses related to the index episode of wheezing (I)  
   A third of the index episodes were related to RSV and another third to rhinovirus 
infection and in most of the RSV- and rhinovirus-positive cases, no other viruses were 
identified (Table 11).  
 
Table 11. Viral aetiology of the index episode of wheezing in 81 
children attending to the follow-up visit in teenage years. 
Viral findings a 
All  
n=81 
RSV, n (%)  25 (31) 
as a single viral finding 17 
in mixed viral infections b 8 
Picornaviruses :  
    Rhinovirus, n (%)  24 (30) 
as a single viral finding  19 
in mixed viral infections c 5 
    Enterovirus, n (%)  10 (12) 
as a single viral finding 5 
in mixed viral infections 5 
Other viruses alone or in combinations, n (%) 8 (10) 
No viral findings, n (%) 22 (27) 
a Antigen detection (RT-FIA) and serology (CF) for RSV, adenovirus, 
influenza viruses A and B and parainfluenza viruses 1-3 performed in all 81 
children.  RT-PCR for RSV performed in 48/81 and RT-PCR for 
picornaviruses in 66/81 children. 
b 1 RSV-rhinovirus, 4 RSV-enterovirus, 2 RSV-parainfluenza virus-3 and 1 
RSV-adenovirus-parainfluenza virus-3 co-infections 
c 1 rhinovirus-RSV, 1 rhinovirus-enterovirus, 2 rhinovirus-adenovirus and 1 
rhinovirus-parainfluenza virus-3-adenovirus co-infections were detected  
 
Teenage asthma was present in 5/25 (20%) of the children if the index episode of 
wheezing in infancy was related to RSV, and in 11/19 (58%) if the index episode was 
related to rhinovirus. The respective figures for PCA were 2/25 (8%) and 9/19 (47%). 
Although aORs were 0.29-0.45 for RSV-related and 1.27-2.51 for rhinovirus-related 
early wheezing, the associations between viral findings during the index episode of 
wheezing and teenage asthma or PCA were not statistically significant (Table 12 and 
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Table 13).  Fourteen of the former 25 (56%) RSV-positive children had at least one 
positive reaction in SPTs in their teenage years, compared to 37/56 (66%, OR 0.65, 95% 
CI 0.25-1.71) of the RSV-negative children. The respective figures were 14/19 (74%) 
and 23/42 (55%) for rhinovirus positive and negative cases, respectively (OR 2.31, 
95%CI 0.71-7.59). 
   The index episode of wheezing was related to RSV in 14/27 (52%) children who 
never experienced asthma in childhood, and the respective figure for rhinovirus 
aetiology alone was 3/27 (11%). In the supplementary analyses, with adjustment for 
age, sex and early atopic dermatitis, where the no PCA group consisted of the “no 
asthma ever” group, early wheezing related to neither RSV ( aOR 0.23, 95% CI 0.04-
1.42) nor to rhinovirus (aOR 2.53, 95% CI 0.37-17.32) was significantly associated with 
PCA.   
 
Table 12. RSV aetiology of the index episode of wheezing in infancy in relation to teenage 
asthma  and PCA. 
RSV  
Teenage asthma PCA 
  
Yes  No  aORb       Yes  No  aORb        
(n=32) (n=49) (95% CI) n=(20) (n=61) (95% CI) 
RSV alone or in 
combinations with other 
viruses, n (%) 
5(16) 20(41) 0.40 2(10) 23(38) 0.40 
  (0.11-1.40)   (0.07-2.20) 
RSV alone, n (%) a 4(13) 13(31) 0.45 1(5) 16(30) 0.29 
(0.11-1.88) (0.03-2.85) 
a The 8 RSV co-infections were excluded from the analyses. The  numbers for teenage asthma/no teenage 
asthma were 31/42, and for PCA/no PCA=19/54. 
b Logistic regression adjusted for sex , age (in months) and atopic dermatitis on admission. After further 
adjustment for passive smoking in infancy, the results remained the same.  
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Table 13. Rhinovirus aetiology of the index episode of wheezing in infancy in relation to teenage 
asthma and PCA. 
Rhinoviruses  
Teenage asthma PCA 
Yes  No  aORc       Yes  No  aORc        
(n=27) (n=39) (95% CI) n=(16) (n=50) (95% CI) 
Rhinovirus alone 1, n (%) a 11(41) 8(21) 1.41 9(56) 10(20) 2.51 
(0.40-4.93) (0.62-10.21) 
Rhinovirus alone 2, n (%) b 11(44) 8(22) 1.39 9(56) 10(22) 1.93 
(0.38-5.10) (0.45-8.21) 
Rhinovirus alone or in 
combinations with other 
viruses, n (%)  
13(48) 11(28) 1.27 9(56) 15(30) 1.30 
  (0.39-4.15)   (0.33-5.20) 
a Rhinovirus alone compared to other viruses, rhinoviruses in combinations or no viral identification. 
b Rhinovirus alone compared to other or no viral identification. Rhinovirus in combinations with other 
viruses excluded from the analyses. The numbers for teenage asthma /no teenage asthma were 25/36, and 
for PCA/no PCA 16/45. 
c Logistic regression adjusted for sex , age (in months) and atopic dermatitis on admission. After further 
adjustment for passive smoking in infancy, the results remained the same.  
 
5.2.4. Atopy in children (I, IV, unpublished data 
 
Atopic dermatitis and serum total IgE (I) 
   As presented in Table 14, atopic dermatitis at the time of the index episode of 
wheezing in infancy was predictive for both teenage asthma and PCA, but serum total 
IgE≥60 kU/L associated significantly only with PCA. 
 
The presence of serum specific IgE to food allergens (I, unpublished data) 
   The presence of serum sIgE of ≥0.35 kU/L to the mixture of food allergens at the time of 
the index episode of wheezing was quite common, but it was not significantly associated 
with the development of teenage asthma or with PCA (Table 15). With respect to the 
individual allergens, cow's milk was predictive for teenage asthma and wheat was a strong 
predictor of both teenage asthma and PCA (Table 15). 
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The presence of serum specific IgE to inhalant allergens (I, unpublished data) 
   The presence of serum sIgE of ≥0.35 kU/L to the mixture of inhalant allergens was 
significantly associated with teenage asthma and PCA (Table 16). Sensitization to 
individual inhalant allergens was rare at the time of the index episode of wheezing in 
infancy, and only the presence of sIgE to dog and cat allergens, which were detectable in 
more than five subjects were included in the analyses. No significant associations were 
found between teenage asthma or PCA and the presence of serum sIgE to either cat or dog 
allergens in infancy (Table 16). 
 
Table 14. Atopic dermatitis and serum total IgE≥60 kU/L at the index episode of wheezing in 
infancy in relation to teenage asthma and PCA. 
Atopy 
Teenage asthma PCA 
Yes  No  aORb       Yes  No  aORb        
(n=32) (n=49) (95% CI) n=(20) (n=61) (95% CI) 
Atopic dermatitis, n(%) 14(44) 8(16) 3.48 11(55) 11(18) 4.53 
(1.20-10.09) (1.42-14.44) 
Serum total IgE ≥60 kU/L a, 
n(%) 
11(37) 5(11) 3.51 10(53) 6(10) 5.82 
  (0.95-12.95)   (1.51-22.42) 
a Data were available for 77/81 children. The numbers for teenage asthma/teenage asthma were 30/47 and 
for PCA /no PCA 19/58.  
b  Logistic regression adjusted for sex and age (in months) on admission 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
Table 15. The presence of allergen-specific IgE antibodies to food allergens measured from the 
73/81 children at the index episode of wheezing in relation to teenage asthma at and PCA. 
Specific IgE of ≥0.35 kU/l 
n=73  
Teenage asthma PCA 
Yes  No  aORa       Yes  No  aORa       
(n=29) (n=44) (95% CI) (n=20) (n=53) (95% CI) 
Food allergens, n(%) 18(62) 16(36) 2.28 14(70) 20(38) 2.66 
 (0.78-6.66) (0.80-8.91) 
Egg white, n(%) 15(52) 13(30) 2.01 12(60) 16(30) 2.38 
 (0.68-5.96) (0.72-7.80) 
Cow's milk, n(%) 13(45) 7(16) 3.43 b 9(45) 11(21) 2.09 
(1.08-10.86) (0.64-6.79) 
Wheat, n(%) 10(34) 1(2) 20.24 c 8(40) 3(6) 9.66 d 
 (2.37-172.86) (2.11-44.14) 
Peanut, n(%) 9(31) 5(11) 2.76 8(40) 6(11) 3.77 
      (0.74-10.29)     (0.98-14.53) 
a  Logistic regression adjusted for sex and age (in months) on admission. Allergens with > 5 positive 
detections are presented.  
After further adjustment with atopic dermatitis on infancy;  b aOR 3.89, 95% CI 1.12-13.50 ,c aOR 13.11, 
95% CI 1.44-119.27, d aOR 6.09, 95% CI 1.21-30.57  
 
 
 
Table 16. The presence of allergen specific IgE antibodies to inhalant allergens measured from 
73/81 children at the index episode of wheezing in infancy in relation to teenage asthma and 
PCA. 
Specific IgE of ≥0.35 kU/l 
n= 73  
Teenage asthma PCA 
Yes  No  aORa       Yes  No  aORa       
(n=29) (n=44) (95% CI) n=(20) (n=53) (95% CI) 
Inhalant allergens, n(%)  11(38) 2(5) 11.30 b 10(50) 3(6) 13.07 c 
 (1.89-67.60) (2.39-71.42) 
Cat, n(%)  4(14) 2(5) 1.93 4(20) 2(4) 3.19 
 (0.292-12.78) (0.47-21.43) 
Dog, n(%) 5(17) 2(5) 2.59 4(20) 3(15) 1.87 
      (0.41-16.48)     (0.32-10.88) 
a  Logistic regression adjusted for sex and age (in months) on admission. Allergens with > 5 positive 
detections are presented. In addition, specific IgE was detectable to birch pollen in 4, timothy grass pollen 
in 1, mugworth pollen in 1, horse dander in in 4 and dust mites in 1 children. 
After further adjustment with atopic dermatitis in infancy;b aOR 7.26, 95% CI 1.11-47.61 ,  c aOR 8.64, 
95%CI 1.44-51.97  
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Early sensitization to cat and dog assessed by serum allergen-specific IgE or positive 
skin prick test reactions (IV) 
   In order to evaluate whether early sensitization to dog or cat is predictive for asthma at 
early teenage or PCA, the data on the presence of serum sIgE to cat or dog at the time of 
the index episode of wheezing and the respective SPT reactions eight months later, at 
the median age of 1.5 years (range 0.8-2.7), were combined. Early sensitization to cat 
and dog was more common among children with asthma at early teenage and among 
children with PCA (28-40%) than in children with no asthma at early teenage or PCA 
(6-8%) (Table17).  
   Only 1/12 (8%) children exposed to cat and 1/18 (6%) children exposed to dog in 
infancy were sensitized to respective allergens by the median age of 1.5 years compared 
to the respective figures of 11/68 (16%, aOR 0.48, 95% CI 0.06-4.14) and 11/62 (18%, 
aOR 0.34, 95% CI 0.04-2.95) for non-exposed children. 
 
Table 17. Early sensitization to cat and dog in relation to teenage asthma and PCA. 
Sensitization a to cat or 
dog n=80 
Teenage asthma PCA 
Yes  No  aORb       Yes  No  aORb       
(n=32) (n=48) (95% CI) n=(20) (n=60) (95% CI) 
Sensitization to cat, n(%)     
 
sIgE≥0.35 kU/L / SPT+ 9 (28) 3 (6) 4.76 c 7 (35) 5 (8) 3.80 
d 
 (1.10-20.58) (0.94-15.30) 
Sensitization to dog, n(%)    
  
sIgE≥0.35 kU/L / SPT+ 9 (28) 3 (6) 4.51 e 8 (40) 4 (7) 5.01 f 
      (0.93-21.93)     (1.07-23.52) 
a Specific IgE to cat or dog at the time of the index epsode of wheezing was available in 73/81 and SPTs 
eight months later in 77/81 children: either sIgE or SPTs were available in 80/81 children.  
b Logistic regression adjusted for sex and age (in months) on admission. Further adjustment with 
parenthal asthma, atopic dermatitis in infancy and RSV aetiology of the index episode of wheezing: c aOR 
5.52, 95%CI 1.15-26.61, d aOR 4.21, 95% CI 0.93-19.07, eaOR=3.00, 95% CI=0.53-17.09, f aOR=2.87, 
95% CI 0.51-16.08. 
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5.2.5. Responses to nebulized bronchodilating agents during the index episode of 
wheezing in infancy (II) 
   Before the crossover trial conducted on admission, there were no significant 
differences in the baseline clinical parameters of the bronchiolitis severity between the 
two acute treatment groups, i.e. infants who received racemic epinephrine (REP and 
PRE groups) and infants who received albuterol (AP and PA) (Table 18). The asthma 
cases at the median ages of 4.0, 7.2 and in the teenage years were evenly distributed 
between these acute treatment groups. Children with teenage asthma had lower 
respiratory rates before the start of the trial compared to children without asthma at that 
age (48.7±9.8 vs. 55.6±10.8, p=0.005), but children with PCA did not differ from 
children without PCA in terms of respiratory rate, oxygen saturation, heart rate or RDAI 
score (Table 19).  
   In the mixed model analyses, RDAI scores had been lower after racemic epinephrine 
and albuterol administrations in children with teenage asthma (5.27 and 5.39, 
respectively) compared to children with no asthma at that age (5.57 and 6.19, 
respectively), whereas the figures were the opposite (6.76 in children with teenage 
asthma vs. 5.59 in non-asthmatics) after placebo administration (p=0.04). The other 
clinical responses to treatment did not differ between children with and without teenage 
asthma (data not shown). Figure 2a shows that, oxygen saturations were higher in 
children with PCA than in children without this disorder after albuterol administration, 
but lower, after racemic epinephrine and placebo administrations (Figure 2a). No 
differences were observed in respiratory rates, RDAI scores, and heart rates between 
those developing later PCA and non-PCA cases (Figure 2b-d).  
   A supplementary analysis was performed by comparing findings between the 20 
children with PCA and the 27 children with no signs of asthma in childhood. No 
differences in pooled responses, including oxygen saturation, to given inhalations 
between children with PCA and no asthma ever were seen. However, the analysis of the 
oxygen saturations assessed 15 minutes after inhalations revealed a statistically 
significant result (p=0.03, data not shown). 
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Table 18. Baseline clinical evaluation (mean±SD) between the two 
therapeutic groups a 
Variables before treatment 
REP/PRE b 
group 
AP/PA c 
group 
n=48 n=52 
Oxygen saturation (%) 93.25±2.21 93.49±1.92 
Respiratory rate (breaths/min) 51.75±9.60 53.22±11.98 
Heart rate (beats/min) 150.70±20.75 150.06±14.04 
RDAI score (points) 8.63±2.83 8.96±3.22 
a There were no statistically significant differences between the groups for 
any variable (independent sample t-test) 
b REP= racemic epinephrine (adrenaline) followed by placebo, PRE= 
placebo followed by racemic epinephrine 
c AP= albuterol (salbutamol) followed by placebo, PA=placebo followed by 
albuterol 
 
 
Table 19. Baseline values (mean±SD) in children with and without 
PCAa 
Variables before treatment 
PCA  No PCA  
n=20 n=61 
Oxygen saturation (%) 93.65±2.11 93.43±2.08 
Respiratory rate (breaths/min) 50.15±8.59 53.71±11.50 
Heart rate (beats/min) 156.00±15.56 149.90±17.62 
RDAI score (points) 9.30±4.00 8.84±2.72 
a There were no statistically significant differences between the groups in any 
of the variables (independent sample t-test) 
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5.2.6. Eosinophilic inflammation during the index episode of wheezing (IV) 
   Among the 81 children attending the clinical follow-up in their teenage years, there 
were 79 children (teenage asthma in 31, PCA in 20) for whom there was data on B-
EOS, 81 children (teenage asthma in 32, PCA in 20) with data on S-ECP and 78 
children (teenage asthma 31, PCA in 19) with data on NPA-ECP measured on 
admission available. Table 20 reveals that all the three markers were higher in children 
aged ≥12 months on admission, in children with atopic dermatitis or serum sIgE to food 
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or inhalant allergens in infancy, in children wheezing with viruses other than RSV and 
in children wheezing specifically with rhinoviruses. No statistically significant 
associations were found between the markers and gender, parental asthma, passive 
smoking during infancy or maternal smoking during pregnancy (data not shown).  
   Children with teenage asthma differed significantly from children with no signs of 
asthma for B-EOS obtained on admission (median 0.410 x 109 cells/L, range 0.050-
2.451 vs. 0.168, 0.060-1.201, p=0.027). The values of S-ECP and NPA-ECP in children 
with teenage asthma did not differ significantly from the corresponding S-ECP (median 
3.7 µg/L, range 1.9-116.6 vs. 3.2, 1.9-33.0, p=0.196) and NPA-ECP (398 ng/g, 33-3950 
vs. 472, 2-2782, p=0.388) values in non-asthmatic children. The values of both B-EOS 
and NPA-ECP were significantly higher in children PCA when compared to children 
without PCA (median 0,531 x 109 cells/L, range 0.005-2.451 vs. 0.197, 0.006-1.201, 
p=0.006 and 926 ng/g, 97-3950 vs. 347, 2-3510, p=0.013). In the case of S-ECP, the 
difference between children with and without PCA did not reach statistical significance 
(5.6 µg/l, 1.9-116.6 vs. 3.20, 1.9-33.0, p=0.054).  
   As seen in Table 21, elevated levels NPA-ECP in infancy were a significant predictor 
of teenage asthma. However, neither elevated B-EOS nor elevated S-ECP was 
predictive for teenage asthma. However, elevated B-EOS, S-ECP and NPA-ECP were 
significant risk factors for PCA. On average, an elevated B-EOS increased the PCA risk 
by 2.9-fold, elevated S-ECP by 6.1-fold and elevated NPA-ECP by 6.7-fold.  All three 
markers were elevated in 8 children, and 6 of them had PCA. 
   As presented in Table 22, none of the three eosinophil activity markers was a 
significant predictor of teenage asthma in the multivariate analyses. An elevated NPA-
ECP level associated significantly with PCA. Instead, the associations between elevated 
B-EOS and PCA, and between S-ECP and PCA, which were significant in the 
univariate analyses, were not robust to adjustments for atopic dermatitis in infancy, 
RSV aetiology of the index episode of wheezing and age on admission.  
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Table 21. Elevated B-EOS, S-ECP and NPA-ECP obtained on admission as predictive 
factors for teenage asthma and PCA 
Elevated eosinophil 
marker on admission  
Teenage asthma PCA 
Yes  No  OR a       Yes  No  OR a       
(n=32) (n=49) (95% CI) n=(20) (n=61) (95% CI) 
B-EOS b, n (%) 12(39) 13(27) 1.70 10(50) 15(25) 2.93 
(0.65-4.46) 1.02-8.42 
S-ECP c, n (%) 6(19) 4(8) 2.60 6(30) 4(7) 6.11 
0.67-10.06 1.52-24.61 
NPA-ECP d, n (%) 13(42) 8(17) 3.52 11(58) 10(17) 6.74 
1.24-9.99 2.16-21.00 
At least one elevated 
marker, n (%) 
19(61) 19(40) 2.33 15(75) 23(40) 4.57 
    0.92-5.90     1.46-14.28 
a Non-adjusted analyses 
b B-EOS was available in 79/81 (teenage asthma in 31, PCA in 20), c S-ECP in 81/81 (teenage asthma 
in 32, PCA in 19) and d NPA-ECP in 78/81 (teenage asthma in 31, PCA in 19) 
 
 
 
Table 22. Logistic regression: Elevated B-EOS, S-ECP and NPA-ECP obtained on admission 
as predictive factors for teenage asthma and PCA 
Elevated eosinophil 
marker on admission  
Teenage asthma PCA 
Yes  No  aOR a       Yes  No  aOR a       
(n=32) (n=49) (95% CI) n=(20) (n=61) (95% CI) 
B-EOS c, n (%) 12(39) 13(27) 0.66 10(50) 15(25) 1.01 
(0.20-2.21) (0.27-3.76) 
S-ECP d, n (%) 6(19) 4(8) 0.92 6(30) 4(7) 1.77 
(0.19-4.51) (0.34-9.12) 
NPA-ECP e, n (%) 13(42) 8(17) 2.17 11(58) 10(17) 4.45 f 
(0.68-6.98) (1.18-16.75) 
At least one elevated 
marker, n (%) 
19(61) 19(40) 1.10 15(75) 23(40) 2.33 
    (0.36-3.33)     (0.61-8.84) 
a Logistic regression adjusted for age on admission, sex, atopic dermatitis in infancy and RSV etiology 
of early wheezing. The markers were analyzed separately. 
c B-EOS was available in 79/81 (teenage asthma in 31, PCA in 20), d S-ECP in 81/81  (teenage asthma 
in 32, PCA in 19) and e NPA-ECP in 78/81 (tenage asthma in 31, PCA in 19) 
After further adjustment for sensitization to either food or inhalant allergens at the time of admission: 
aOR 4.97, 95%CI 1.18-20.95 f 
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5.2.7. Neutrophil activation measured by serum myeloperoxidase (VI) 
    Of the original 100 children enrolled into the present study, there were S-MPO results 
on admission available for 98 children, and 6 weeks, 4 months and 12 months later, for 
94, 89 and 90 children, respectively. The level of S-MPO1 was higher in children aged 
≥ 12 months, in children with serum sIgE to food or inhalant allergens and in children 
with wheezing induced by rhinoviruses, compared to children without these 
characteristics (data not shown). However, children with exposure to ETS before 
hospitalization for wheezing had lower S-MPO1 values compared to children with no 
such exposure (median 241.5 µg/L range 107.2-829.6 vs. 315.5, 136.6-1051.4, 
p=0.007). When each variable was included separately into the age-adjusted analyses, 
all other significant associations disappeared (data not shown), except for the 
association between exposure to ETS in infancy and LogMPO1 (p=0.007). No 
statistically significant associations were seen between MPO at any of the four 
measurements and maternal smoking during pregnancy, exposure to maternal smoking 
in infancy, gender, parental asthma or atopy, atopic dermatitis in infancy or RSV 
identification (data not shown).  
   The S-MPO concentration was highest on admission and significantly decreased 
thereafter. According to the repeated measures ANOVA, the decrease in LogMPO was 
significant between the measurements 1 and 2 as well as between measurements 3 and 4 
(Figure 4). 
   The levels of S-MPO1, S-MPO2, S-MPO3 and S-MPO4 did not differ between 
children with and without teenage asthma or PCA (data not shown).  The effect of the 
early four-month intervention on the change in LogMPO was analyzed by the repeated 
measures ANOVA, and there were no significant differences between the budesonide, 
cromolyn sodium and control groups (data not shown). Finally, the changes in LogMPO 
measured in infancy were analyzed in relation to the appearance of later asthma 
adjusted for age on admission (<12 months/ ≥12 months), atopic dermatitis in infancy 
and RSV aetiology of the index episode of wheezing in nfancy. In repeated measures 
ANOVA, the changes in LogMPO showed an identical pattern between children with 
and without teenage asthma (data not shown), and as presented in Figure 5, the changes 
in LogMPO were nearly identical in children whether or not they had PCA.  
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5.2.8. Early-life predictive factors for abnormal lung function and bronchial 
hyper-reactivity (III) 
   Parental history of asthma, maternal smoking during pregnancy, early exposure to 
ETS, elevated serum total IgE, the presence of serum sIgE to inhalant or food allergens, 
elevated NPA-ECP or elevated S-ECP on admission or the presence of atopic dermatitis 
on admission, were not significantly associated with any parameter in FVS (data not 
shown).  There was a trend that elevated B-EOS, assessed on admission, was associated 
with lower FEV1 (89.54 (mean, % of predicted) ± 12.11 (SD) vs. 93.64 ± 13.48, 
p=0.081), MEF50 (76.16 ± 18.32 vs. 83.81 ± 19.33, p=0.059) and MEF25 (64.98 ± 19.08 
vs. 74.72 ± 21.11, p=0.065). RSV aetiology of the index episode of wheezing in infancy 
was associated with a higher FEV1/FVC and a lower FVC when compared with non-
RSV aetiology (Table 23). There were no statistically significant differences in any 
baseline FVS parameters between rhinovirus positive and negative cases (data not 
shown). 
 
Table 23. Findings in the baseline FVS in teenage years in relation to RSV- and 
non-RSV aetiology of the index episode of wheezing in infancy.  
Parameters in FVS RSV+ a RSV-   
% predicted, mean ±SD n=24 n=56 p b 
FVC 93.65±11.05 99.57±12.59 0.009 
FEV1 91.87±10.65 92.39±13.93 0.267 
FEV1/FVC 98.35±6.53 92.91±8.70 0.033 
MEF50 85.81±17.62 79.56±19.43 0.802 
MEF25 77.78±20.35 69.07±20.34 0.303 
a Mixed infections included 
b ANOVA adjusted for age on admission (<12/≥12 months), atopic dermatitis in infancy 
and their interactions with RSV aetiology of the index episode of wheezing in infancy. 
 
 
   None of the early-life risk-factors was a significant predictor of abnormal lung 
function, as defined as one or more abnormal value in the FVS parameters (data not 
shown).  
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   The early-life factors were tested also as predictors of BHR to exercise and to 
methacholine. As shown in Table 24, the presence of serum sIgE to inhaled allergens on 
admission and maternal smoking during pregnancy were associated with BHR to 
exercise, and furthermore atopic dermatitis in infancy was associated with intermediate 
to high BHR to methacholine. No other early-life risk factor, present during the index 
hospitalisation, was predictive of BHR in teenage years (data not shown). 
 
Table 24.Early-life risk factors for BHR in teenage years. 
Early-life risk-factors, present/tested BHRa aOR b 95% CI 
Positive ECT (Fall in FEV1≥10%) 
Serum sIgE (≥0.35 kU/L) to inhalant allergens, 13/73  10 12.57 2.30-68.77 
Maternal smoking during pregnancy, 17/18 8 4.58 1.28-16.39 
 Positive MIC test (PD20<1600μg) 
Atopic dermatitis in infancy, 19/69 13 3.48 1.09-11.10 
a ECT=Exercise challenge test, MIC= Methacholine inhalation challenge 
b Logistic regression adjusted for sex and age (<12/≥12 months) on admission. 
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6. DISCUSSION 
 
 
6.1. Methodological aspects 
6.1.2. The study design 
   One hundred children requiring hospitalization for wheezing during an acute 
respiratory tract infection at age less than two years were recruited to the present 
prospective follow-up study. The study was originally planned to address the problems 
faced daily by paediatricians working in hospital: How to treat young wheezing 
children, and how to prevent recurrent bronchial obstructions? Because of this clinical 
approach, a positive viral identification was not an inclusion criteria and previous 
wheezing was not an exclusion criteria. However, with the availability of advanced 
methods, the viral identification rate was 73 % for the 81/100 children of the present 
study. In most of the cases, the index episode of wheezing in infancy was the first: 88% 
of the children of the present study had not wheezed before. The recruitment period 
lasted for almost two years, and children were recruited during and between two RSV 
outbreaks.  
   Despite the long (median 11.4 years) follow-up of the children, the attendance rate 
was as high as 81/100 (81%). The basic characteristics and laboratory findings of the 19 
drop-outs at the time of the index episode of wheezing in infancy did not differ from 
those of participating children, except for maternal smoking, which was more common 
in the drop-outs (56% vs. 28%, p=0.027). The present study did not include healthy 
non-wheezing controls. 
    Asthma in teenage years was strictly doctor-diagnosed; the child needed to be on 
continuous or intermittent anti-inflammatory asthma medication, or needed to have 
repeated wheezing symptoms, and to have an objective evidence of asthma. Persistent 
childhood asthma, PCA, was regarded as being present if the child had doctor-
diagnosed asthma, at both of the two previous follow-up visits at the median ages of 4.0 
and 7.2 years and also in the present study in their teenage years. All other children, 
including 12 children with teenage asthma, were included in the non-PCA group. 
   Since the study group was highly selected, i.e. children hospitalized for wheezing in 
infancy, our results reflect only the outcome in children who suffered a clinically severe 
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form of bronchiolitis or early wheezing. Since the Kuopio University hospital is the 
only hospital which provides care for acute viral wheeze requiring hospitalization in the 
area of north-eastern Finland, the results of the prospective follow-up of the present 
hospital-based cohort do provide representative information at the population level on 
the outcome of early severe wheezing.   
 
 6.1.3. Strengths of the study 
   On admission, one of the four investigators decided whether the patient was suitable 
for inclusion in the study, and performed the pre-treatment and post-treatment 
evaluations. The evaluations consisted of measurements of respiratory rate, heart rate 
and oxygen saturation (Reijonen et al. 1995). In addition, a standardized RDAI scoring 
based on two respiratory variables, wheezing and retractions, was utilized (Lowell et al. 
1987). The inter-observer variation was small: the two investigators did not differ in 
ratings by more than one unit in the eight-point retraction scale and the nine-point 
wheezing scale. The κ-values of 0.82-0.87 indicated excellent agreement. In addition, 
the administration of the medication was double-blind (Reijonen et al. 1995).  
   A variety of clinical and laboratory data related to allergy, eosinophil and neutrophil 
activation and viral aetiology of the index episode of wheezing were collected on 
admission (Reijonen et al.1997b, Kotaniemi-Syrjänen et al. 2002, 2003a, 2003b and 
2005). Only diagnoses made by a physician were considered when the history of atopic 
dermatitis and earlier wheezing as well as the parental history of asthma and allergy 
were being recorded (Reijonen et al. 1996). Before the present follow-up visit, a 
structured questionnaire was filled in by the study subjects and their parents, and all the 
answers were checked thoroughly at the clinical visit.  The criteria for the presence of 
teenage asthma were rather strict, and self-reported wheezing symptoms needed to be 
combined either with continuous or intermittent asthma medication or a pathological 
result in the exercise challenge test in the free running outdoors. This test has been 
specific but not very sensitive for the diagnosis of asthma, and the 10-15 % falls in 
FEV1 have been used as cut-off points (Godfrey et al. 1999). In order to improve the 
sensitivity of the test, we chose a 10 % limit for the present study. FVS was performed 
twice, two weeks apart, with nearly identical results, and BHR was studied by two 
different methods, by ECT and MIC test. 
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   There are only two previous studies with corresponding designs and long, over 10 
years, follow-ups, as was the case in the present study. Both the Swedish and Finnish 
post-bronchiolitis studies with follow-up lasting until adulthood have provided 
important information on the early-life risk factors for asthma (Piippo-Savolainen et al. 
2004, Goksör et al. 2006). However, in the Swedish study, early sensitization to 
allergens and eosinophilic markers were not studied, and in both the Swedish and 
Finnish studies, advanced viral diagnostic methods were not available at the time of 
recruitment. In addition, data on neutrophilic markers and early-life responses to 
medication were not available in either study. 
 
6.1.4. Shortcomings of the study 
   The main shortcoming of the present study was the absence of a non-wheezing control 
group. However, the prevalence of asthma at the age of 7 to 12 years has been carefully 
studied in our area in two epidemiological population-based studies, and the prevalence 
of asthma at school age is known to be between 4.0-5.0 % (Timonen et al. 1995, Remes 
and Korppi 1996). Confirmation of these values came in a more recent study performed 
in our area; asthma prevalence was about 5 % at the age of 13-14 years (Lai and the 
ISAAC Phase Three Study Group 2009). Thus, the present study focused on predictive 
factors within the study group, but it was also possible to compare asthma in these 
children with carefully studied asthma prevalence in the same area. 
   Although the asthma criteria were strict, the inclusion of the children with 
maintenance anti-inflammatory asthma medication may have biased the results, at least 
with respect to lung function tests and tests of BHR. However, over 75 % of the 
children with either continuous or intermittent asthma medication had either 
experienced repeated episodes of wheezing, prolonged cough or a positive result in the 
ECT. In addition, measurable BHR was more common in children with continuous or 
intermittent asthma medication than in those children with no maintenance medication 
for asthma.  
   We consider PCA, such as defined in the present study, to be a very reliable measure 
of chronic atopic asthma in childhood. In the present study, 95 % of the children with 
PCA had at least one positive result in the SPTs. However, the classification of the 12 
children with teenage asthma in to the non-PCA group may have biased the results. In 
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the supplementary analyses, exclusion from the analyses of those children with teenage 
asthma but without PCA did not change the results. Further, when only the children 
with no asthma at any time formed the non-PCA group, the results remained almost the 
same. 
 
6.2. Long-term outcome of early childhood wheezing in comparison with other 
long-term studies 
 
Wheezing symptoms and asthma 
     In the present study, asthma was present in 40 % of the children in their teenage 
years after experiencing wheezing requiring hospitalization in infancy. Similar figures, 
30-40%, for self-reported wheezing in teenage years after wheezing at the age of less 
than three years of age, have been reported in population-based cohorts (Morgan et al. 
2005, Matricardi et al. 2008). In the previous follow-up studies, it was found that after 
wheezing requiring hospitalization in infancy, the asthma prevalence has been 17-39 % 
when the children are teenagers (Gurwitz et al. 1981, Noble et al. 1997, Wennergren et 
al. 1997, Sigurs et al. 2005). 
   In the present cohort, the occurrence of asthma was 51 % at pre-school age, and 40 % 
both at early school age and in teenage years.  During the follow-up, 25 % of the cases 
had asthma at all three follow-up visits, i.e. from pre-school age until they were in their 
teens. Our results are in accordance with the Tucson birth cohort, in which about 25 % 
of the children with wheezing at age less than three years were wheezing still both at 
age six and at age 11 years (Morgan et al. 2005). The persistence of asthma has not been 
evaluated in other studies. In most hospital-based cohorts, unlike in the present study, 
the asthma prevalence has decreased between the start of school and the teen years 
(Wennergren et al. 1992 and 1997, Noble et al. 1997, Korppi et al. 1994, Hyvärinen et 
al. 2005), and increased only in one study (Sigurs et al. 2000 and 2005). In the Swedish 
and Finnish cohorts followed up until adulthood, the asthma prevalence increased again 
in the period between the teenage years and adolescence (Goksör et al. 2005, Piippo-
Savolainen et al. 2006).   
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Atopy at early teenage 
   In Eastern Finland, the prevalence of SPT positivity to at least one aeroallergen at age 
7-16 years has been 43-52 % (Remes and Korppi 1996, von Hertzen et al. 2006). In the 
present selected cohort, allergic sensitization in teenage years was more common: 63% 
of the children were sensitized to at least one aeroallergen, and 90-95 % of the children 
with teenage asthma or who had PCA had at least one positive SPT reaction compared 
to 45-51% of those without teenage asthma or PCA, respectively. In two other hospital-
based cohorts, the sensitization figures in teenage years have been lower, 44 % to 50 % 
(Noble et al. 1997, Sigurs et al. 2005). These studies included only infants admitted at 
less than 12 months of age, compared to the age range of 1 to 23 months in the present 
study. Thus, because there is an increasing number of wheezing children at age 1-2 
years who are atopic, probably more of these subjects were recruited into the present 
study. 
 
Lung function and bronchial hyper-reactivity 
   In the present study, the mean values in FVS, measured over 11 years after severe 
early wheezing, were within the normal limits compared to gender-specific and height-
related reference values for Finnish children. However, as many as 33 % of the children 
had one or more abnormal values in the FVS. Furthermore, BHR measured by two 
methods, was common, being present in 27 % of cases to exercise and in 46 % to 
methacholine. These values were rather similar to that of 37 % in another hospital-based 
study with a corresponding design (Wennergren et al. 1997).  
   In the population-based birth cohorts, forced expiratory flows have been lower in 
children with a history of LRTIs and/or wheezing compared to children with no such 
history (Stein et al. 1999, Morgan et al. 2005, Håland et al. 2009). In hospital-based 
studies after an episode of wheezing in infancy either due to RSV (Sigurs et al. 2005) or 
any respiratory virus (Noble et al. 1997), when compared to matched controls, lowered 
forced expiratory flows and BHR have been reported in teenage years. In addition, in 
line with the figures of present study, in the Finnish and Swedish bronchiolitis cohorts 
followed-up until adulthood, abnormal lung function parameters in the FVS were seen 
in 31-36 % of the study subjects, compared with 11-16 % in the control subjects, 
(Piippo-Savolainen et al. 2004, Goksör et al. 2008).  
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6.3. Early-life predictive factors for asthma 11 years after hospitalization for 
wheezing in comparison with other long-term studies 
6.3.1. Age on admission, parental history of asthma and atopy, and environmental 
factors in comparison with other studies 
 
Age and parental history of asthma 
   In the Tucson birth cohort, recurrence of wheezing became more common with 
increasing age at the first wheezing episode (Taussig et al. 2003). Likewise, children 
with teenage asthma and PCA were older (> 12 months) on admission, compared to the 
children who remitted in the present study. An increasing number of asthma risk factors 
become involved between the age 1-2 years (Jartti et al. 2009), which probably explains 
the association between age on admission and later asthma.  However, in the study of 
Wennergren et al., hospitalization for wheezing at a young age (< six months) was 
associated with asthma at age 10 years (Wennergren et al. 1997), and Sigurs et al. 
included only young infants, mostly less than six months of age, and RSV bronchiolitis 
was still a risk factor for asthma at age 13 years (Sigurs et al. 2005). These results point 
to either the presence of a common underlying factor, probably genetic, involved in 
both severe bronchiolitis and asthma, or an interaction of an early viral infection with 
the developing immune system and allergic sensitization (Sigurs et al. 2005, Juntti et al. 
2005 and 2009). 
   In most earlier long-term population-based cohorts (Taussig et al. 2003, Matricardi et 
al. 2008) and in hospital-based cohorts (Sigurs et al. 2005, Goksör et al. 2008, Piippo-
Savolainen et al. 2006), a family history of asthma and atopy, in particular asthma in the 
parents, has been predictive for asthma. In the present study, there was a tendency for 
parental and maternal asthma, but not atopy in parents, to be associated with teenage 
asthma and PCA in children after wheezing in infancy. The statistically non-significant 
result was probably due to insufficient power of the present study, since asthma in 
parents was rare. Atopy, in contrast, was common in parents, permitting a reliable 
statistical assessment.  
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Environmental factors 
   In the Tucson birth cohort, maternal smoking, recorded at one year of age, was 
associated with transient wheezing at less than three years of age, and also with 
persistent wheezing until age six (Martinez et al. 1995), but exposure to environmental 
tobacco smoke was not detected as a risk factor for persistent wheezing in a longer 
follow-up. In the birth cohort from Germany, parental smoking in infancy was not a risk 
factor for wheezing at age 13 (Matricardi et al. 2008). However, the Finnish and 
Swedish follow-up studies until adulthood have stressed the role of exposure to 
environmental tobacco smoke (Piippo-Savolainen et al. 2006, Goksör et al. 2007), 
especially maternal smoking during pregnancy (Goksör et al. 2007) as important risk-
factors for asthma and impaired lung function. In the Swedish cohort, postnatal 
exposure to environmental tobacco smoke seemed to act through increasing the risk of 
active smoking in adolescence, whereas pre-natal tobacco smoke exposure seemd to 
influence the development of BHR (Goksör et al. 2007). In the present study, exposure 
to environmental tobacco smoke in infancy was common, 46 %, and carried a slightly 
increased risk of asthma and PCA. Active smoking was very common in Finnish and 
Swedish cohorts followed up until adulthood; 27-28 % of the cases smoked, which 
complicates the evaluation of the role of early exposure to environmental tobacco 
smoke. None of the children in their teenage years reported active smoking in the 
present study. 
   The three-year follow-up of the present cohort revealed that exposure to a furry pet at 
home before the index episode of wheezing in infancy was related to less asthma 
(Reijonen et al. 2000), but at age six the protective effect was no longer significant 
(Kotaniemi-Syrjänen et al. 2002). In the present study when the children were in their 
teenage years, PCA was more common in children with no exposure to dogs (28%) in 
infancy than in exposed children (5%). However, after adjusting for confounding factors 
such as parental atopy and personal early atopy, the difference was not significant, 
suggesting “a healthy pet owner effect”, i.e. there is less pet keeping in atopic families.  
However, in accordance with the present results, exposure to furry pets in infancy has 
not increased the asthma risk at age 10-13 years (Wennergren et al. 1997, Sigurs et al. 
2005) or in adolescence (Goksör et al. 2007, Piippo-Savolainen et al. 2007a) after 
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hospitalization for wheezing in infancy, as was also reported in the German birth cohort 
(Matricardi et al. 2008). Furthermore, early exposure to cats or dogs did not increase 
sensitization to these allergens at any phase of the present follow-up.  
 
6.4. Viruses related to the index episode of wheezing in comparison with other long 
term studies 
 
RSV 
   In the present study, an RSV aetiology of the index episode of wheezing was 
associated with a relatively better outcome than in those with other or no viral findings: 
Teenage asthma was present in 20 % and PCA in 8 % of the children after RSV-related 
early wheezing, which was less than the values of 48 % and 32 %, respectively, if the 
wheezing had been attributed either to some other or to no viral findings. However, 
compared to the 4-5 % asthma prevalence in the non-selected child population in 
eastern Finland (Remes and Korppi 1996, Lai and the ISAAC steering committee 2009), 
the risk of teenage asthma was still four-fold, and the risk of PCA was two-fold after 
hospitalization for RSV induced early wheezing. In accordance to our results, other 
hospital-based prospective long term follow-ups have reported more favourable 
outcomes after RSV-induced early wheezing than after wheezing with other or no 
viruses, but in some cases no differences have been detected in asthma prevalence 
(Wennergren et al. 1997, Hyvärinen et al. 2005, Piippo-Savolainen et al. 2007b). In the 
Tucson birth cohort, infants with RSV-LRTI during the first three years of life were 
more likely to suffer from wheezing up to the age of 11 years, but no longer at the age 
of 13 (Stein et al. 1999). In the study of Sigurs et al., hospitalization for RSV 
bronchiolitis at less than age one year was a risk factor for asthma at least up to 13 years 
of age. However, a reduction in risk ratios was seen with increasing age (Sigurs et al. 
1995, 2000 and 2000), pointing to  a disappearance of the effect of early RSV infection 
with increasing age, which is in accordance with conclusions of a recent review (Perez-
Yarza et al. 2007) and with the Tucson birth cohort study (Stein et al.1999).  
   In the present study, RSV-positive cases were as likely to be sensitized to any 
aeroallergen in teenage years as were non-RSV-cases. Other studies have reported also 
similar (Stein et al. 1999, Korppi et al. 2004) or an even lower (Juntti et al. 2003) 
prevalence in SPT positivity in RSV cases. In contrast, in the study of Sigurs et al., 
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sensitization to common aeroallergens was more frequent in the RSV group than in the 
control group (Sigurs et al. 2005). However, in comparison with the population data 
(von Hertzen et al. 2006), the prevalence of atopic sensitization in the control group was 
low, 28 %, and not very high (50%), in the RSV cases (Sigurs et al. 2005). 
 
Rhinovirus 
   There are no population-based long-term follow-up studies on the association between 
early rhinovirus-induced wheezing and subsequent asthma, since molecular viral 
diagnostics for rhinoviruses were not available before the 1990s. In the childhood 
origins of asthma cohort, a birth cohort consisting of infants with at least one atopic 
parent, it was demonstrated that rhinovirus-induced viral wheezing not requiring 
hospitalization was a significant predictor of asthma at age six years (Jackson et al. 
2008). In another high-risk cohort, wheezing induced by rhinovirus alone or in 
combination with RSV at less than one year of age was associated with wheezing at age 
five years, but only in children sensitized at less than two years of age (Kusel et al. 
2007). The authors concluded that viral infections interact with atopy in infancy to 
promote subsequent asthma.   
   In the present cohort at early school age, asthma was more common after rhinovirus-
induced wheezing compared to the wheezing caused by RSV or other viruses (52% vs. 
15 %) (Kotaniemi-Syrjänen et al. 2003b). In the present study, teenage asthma (58%) 
and PCA (47%) were still more common after rhinovirus aetiology of early wheezing 
compared to other or no viral aetiology (33% and 17%, respectively teenage asthma and 
PCA), but the differences were no longer statistically significant. In the present cohort, 
we noted that rhinovirus aetiology of early wheezing was more common among infants 
aged more than 12 months, among infants with early atopic dermatitis and among 
infants with elevated eosinophil markers on admission. Thus, rather than being an 
independent risk factor for asthma, rhinovirus-induced wheezing in infancy is probably 
a marker identifying those children prone to wheeze due early respiratory allergy, 
ongoing eosinophil airway inflammation or even early structural changes in the airways. 
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6.5. History of atopic dermatitis, serum total IgE and early sensitization to 
allergens in comparison with other studies 
      In the present study, early atopic dermatitis and elevated serum total IgE, assessed at 
the time of the index episode of wheezing in infancy, predicted teenage asthma and 
PCA. Similarly, atopic dermatitis and elevated serum total IgE at age one were 
predictive for persistent wheezing in the Tucson birth cohort (Martinez et al. 1995). In 
the study of Wennergren et al., atopic diseases in early childhood were not predictive 
for asthma at age 10 (Wennergren et al. 1997). In other hospital-based long term follow-
up studies, the role of early atopy on asthma at age 10-13 years has not been evaluated, 
or has been studied poorly (Gurwitz et al. 1981, Noble et al. 1997, Wennergren et 
al.1997, Sigurs et al. 2005, Goksör et al. 2006). 
   In the present study, early sensitization to inhaled allergens was rare, being present in 
18 % of the infants, but highly predictive for teenage asthma and PCA. Sensitization to 
aeroallergens at the time of admission was rare, being exhibited only in infants aged 
more than 12 months. In order to evaluate the role of early sensitization to cat or dog 
allergens as predictors of teenage asthma and PCA, the data of SPTs at the median age 
of 1.5 years were combined to the serum sIgE data obtained in infancy. About a third of 
children with early teenage asthma or PCA were sensitized to cat or dog allergens, 
compared to less than 10 % of non-asthmatics. Early sensitization to cats was a 
significant predictor of teenage asthma, and sensitization to dog was predictive of PCA. 
Our findings are in accordance with the findings from the German birth cohort, which 
reported that early sensitization to perennial allergens, including cat dander, was a 
strong risk factor for persistent wheezing in children with a history of early wheezing 
(Matricardi et al. 2008). In the Finnish post-bronchiolitis cohort, which was followed up 
until adulthood, sensitization to inhaled allergens at age less than three years was 
predictive for asthma until the teenage years, but not thereafter, but in contrast to the 
present study, no associations were seen between sensitization to furry pets and later 
asthma (Piippo-Savolainen et al. 2007a).  
   In the present study, sensitization to food allergens was common, being present in 47 
% of the infants, but predictive of teenage asthma or PCA only when serum sIgE to 
individual food allergens were present. Sensitization to cow′s milk predicted teenage 
asthma and wheat was a strong predictor of both, teenage asthma and PCA. 
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Sensitization to egg white, which had been predictive for asthma when the children 
started school (Kotaniemi-Syrjänen et al. 2003a), was no longer significant. In another 
Finnish cohort, IgE-mediated clinical cow′s milk allergy was a risk factor for school age 
asthma and allergic sensitization (Saarinen et al. 2005).  A detection limit was applied in 
the present study, and low to moderate sIgE rises might be found in infancy without any 
clinical consequences (Kulig et al. 1999). In the German birth cohort study, higher 
concentration limits were applied, and early sensitization to food allergens in infancy 
predicted the persistence of wheezing in the univariate analyses, but no longer in a 
stepwise model including also early sensitization to perennial allergens (Matricardi et al. 
2008). Consequently, the presence of low concentrations of serum sIgE to food 
allergens early in life probably reflects atopic diathesis before there are any clinical 
manifestations or aeroallergen sensitization (Kulig et al. 1999). In the present study, 
about a third of infants with serum sIgE to food allergens and/or to wheat had also 
serum sIgE to inhalant allergens, but by their teenage years about 80 % of the children 
displaying serum sIgE to food in infancy and all of the 11 wheat-positive children in 
infancy had become sensitized also to aeroallergens. 
 
6.6. Responses to bronchodilating agents during the index episode of wheezing as 
predictors of later asthma 
   Increased BHR, when measured shortly after wheezing in infancy, was related to the 
development of later asthma in infants with an atopic predisposition (Saga et al. 2001). 
In the present study, we were not able to confirm the hypothesis that future asthmatics 
respond better than future non-asthmatics to inhaled bronchodilators during acute 
bronchial obstruction at age less than 24 months. However, we observed that oxygen 
saturation was higher after albuterol inhalations in children with later persistent asthma 
compared to the situation in children who did not develop persistent asthma, but lower 
after placebo and racemic epinephrine inhalations. Thus, there might be a subset of 
infants whose airways are susceptible to reversible smooth muscle contraction which 
will progress later to asthma. However, the absolute differences in oxygen saturations 
between children with PCA and no PCA were small, and not clinically relevant.  
   In asthma, the smooth muscle constriction is related to basement membrane 
thickening, epithelial damage and eosinophilic airway inflammation, and these changes 
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may ocur even in young children and infants (Barbato et al. 2006, Saglani et al. 2007). 
In a Norwegian study, an early bronchodilator response, as evaluated by tidal lung 
function measurements in asymptomatic children less than two years of age, was 
associated with recurrent bronchial obstruction, but not with allergic sensitization or 
atopic dermatitis (Lodrup Carlsen et al. 2004). The authors concluded that recurrent 
bronchial obstruction in infancy may be more closely associated with lung function 
abnormalities, like BHR, than with asthma at school age, which the authors believed 
was more closely linked with allergic sensitization (Lodrup Carlsen et al. 2004). 
However, the early bronchodilator responses with regard to later asthma status of the 
children were not, unfortunately, reported in that study. In the present study, asthma 
status was assessed three times over an 11 year-period after early wheezing, but the 
evaluation of early bronchodilator responses was based solely on clinical findings. 
Therefore, more follow-up studies with the appropriate methods for the measurement of 
bronchodilating response in infants are needed to study whether there is a significant 
link between early-life responses to bronchodilating agents and later asthma. 
 
6.7. Eosinophilic inflammation during the index episode of wheezing as a 
prediction of later asthma  
  It is unclear which age is critical for the development of eosinophilic inflammation and 
permanent structural changes in the airways of wheezing children. In recent biopsy 
studies, evidence was found that the age from one to three years is probably the most 
critical period, since no changes were seen even in those children with a history of 
severe wheezing younger than 12 months, but they were demonstrated in wheezing 
children by three years of age (Saglani et al. 2007). Accordingly, in the present study, 
eosinophils and their activity markers measured in blood and nasopharyngeal aspirates 
in severely wheezing infants were higher in children aged more than 12 months. 
Further, high levels of eosinophil activity markers were also related to other asthma risk 
factors, such as atopy and wheezing with rhinovirus, which became more common with 
increasing age.  
   Based on the results from birth cohort studies, blood eosinophilia in early life has been 
included as a minor risk factor in the algorithms for starting asthma therapy in young 
children with repeated wheezing (Gastro-Rodriguez et al. 2000, Guilbert et al. 2004). In 
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hospital-based follow-up studies, as seen also in the earlier phases of the present cohort, 
both blood eosinophilia (Kotaniemi-Syrjänen et al.2002, Ehlenfield et al. 2000) and 
elevated serum ECP (Reijonen et al 1997a) have predicted the continuation of wheezing 
and asthma symptoms between five to seven years of age. In the few long-term follow-
ups available, neither blood eosinophilia nor elevated serum ECP documented at less 
than 24 months of age, were associated with asthma at age 10 years (Wennergren et al. 
1997). Likewise, no association was seen between blood eosinophilia in infancy and 
later asthma in a Finnish post-bronchiolitis cohort followed-up until adulthood, but the 
lack of an eosinopenic response to infection in infancy was a significant risk factor for 
asthma in adulthood (Piippo-Savolainen et al. 2007c). In the present study, blood 
eosinophilia and elevated serum and nasopharyngeal ECP at less than 24 months of age 
predicted PCA, but elevated nasopharyngeal ECP predicted both teenage asthma and 
PCA. However, in the multivariate analyses, only nasopharyngeal ECP was 
significantly associated with PCA, but not anymore with teenage asthma. 
   Although there is evidence that inflammatory markers in the nasal epithelium may 
reflect airway pathology (Frischer et al. 2000), samples obtained from the upper airways 
allow only an indirect assessment of the situation in the lower airways. In addition, the 
methods are poorly standardized.  However, nasopharyngeal aspirates are easy to obtain 
and routinely used for viral studies, and we collected samples by aspirating mucus from 
the nasopharynx, near to the glottis. Since there were no reference values available for 
NPA-ECP, the concentrations were expressed per weight of mucus sample, and the 
value 815.0 ng/g resulted from the ROC curves was applied.  Though ECP in 
respiratory secretions may reflect lower airway inflammation better than the 
corresponding values in blood or serum, only a few studies are available on nasal, 
nasopharyngeal or sputum ECP as risk factors of asthma in children with early-life 
wheezing. In the study of Sigurs et al., nasal ECP was not associated with bronchial 
symptoms two years after RSV bronchiolitis (Sigurs et al.1994), but did predict 
recurrent wheezing after bronchiolitis for at least four months in the present cohort 
(Reijonen et al. 1997b). 
   In the present study, eosinophils and the eosinophil markers during wheezing in 
infancy were non-sensitive but rather specific predictors of teenage asthma and PCA, 
with sensitivities varying from 13 % to 58% and specificities from 73% to 93%. When 
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combined, these markers identified 61% of the children with teenage asthma and 75% 
of the PCA cases. Elevated serum ECP did not detect additional teenage asthmatics or 
PCA cases better than elevated blood eosinophils and NPA-ECP, but in fact more than 
one third of the PCA cases were recognized by elevated nasopharyngeal ECP values 
alone. This means that NPA-ECP identified different patients than detected by S-ECP or 
blood eosinophils.  
 
6.8. Neutrophil activation in infancy, measured by serum MPO, as a risk factor for 
later asthma  
   The results of the present study revealed that serum levels of MPO, measured on 
admission and thereafter three times when the infants were healthy, was highest during 
acute wheezing, but this elevation occurred equally in future asthmatics and non-
asthmatics. After the acute infection, the serum MPO value decreased, and was 
constantly lower thereafter, showing no connection to anti-inflammatory treatment or 
future asthma. Thus, the high serum MPO concentrations measured during acute 
infection most probably reflected a reaction to inflammation, and correspondingly, the 
subsequent measurements reflected the recovery of inflammation. Accordingly, there 
are higher serum MPO levels in asthmatics with an acute infection compared to the 
corresponding values in asthmatics with no acute infection (Tauber et al. 1999). In 
addition, the serum MPO value was higher in children with symptomatic asthma, when 
compared to children with episodic or non-symptomatic asthma (Carlsen et al. 1997, 
Kalayci et al. 2000), suggesting an involvement of neutrophilis in asthmatic 
inflammation, possibly related to viruses.  In the study of Sigurs et al., serum MPO 
increased during RSV bronchiolitis, and decreased within a few weeks thereafter, and 
MPO at any level was not predictive for subsequent wheezing or asthma in the two-year 
follow-up (Sigurs et al. 1994). In accordance, serum MPO at any level in any 
measurement in infancy was not able to predict either the presence or absence of 
teenage asthma or PCA in the present study. Thus, MPO appears to be a marker of acute 
infection, and unlike eosinophils, not useful in the prediction of the development of 
atopic asthma after wheezing in infancy.     
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6.9. Risk factors for lung function abnormalities and bronchial hyper-reactivity in 
comparison with other studies 
   In the population-based Tucson birth cohort study, LRTI caused by RSV in infancy 
was predictive for decreased forced expiratory flows at age 11 years (Stein et al. 1999). 
Further, Sigurs et al. found that infants hospitalized for RSV bronchiolitis at less than 
12 months of age, had lower FEV1/FVC and maximal expiratory flows at 75 % of FVC 
compared to controls at age 13 (Sigurs et al. 2005). In addition, FEV1/FVC and MEF25, 
were lower in subjects with a history of RSV bronchiolitis compared to controls in the 
Finnish post-bronchiolitis cohort followed up until adulthood (Korppi et al. 2004b). In 
the present study, in contrast, early wheezing related to RSV seemed to be associated 
with a restrictive pattern of lung function, as reflected by the significantly decreased 
FVC values in conjunction with the normal FEV1 values and even elevated FEV1 / FVC 
values. In the present cohort, subjects with teenage asthma or PCA, in contrast, had high 
FVC values and low FEV1/FVC values compared to non-asthmatics, including most 
RSV positive cases. The FVC values were within normal limits in both groups, which 
obscures the clinical significance of the findings. However, in the German birth cohort 
study, FVC growth velocities were higher among children with asthma than among 
children without asthma until the age of 12-14 years (Strunk et al. 2006), and the FVC 
growth velocity pattern comparable to the subjects in the German study could explain 
our findings. On the other hand, the evidence of restriction found in the present study, as 
well as similar findings in other studies, may reflect pre-morbid structural changes in 
infants susceptible to severe RSV infection (Taussig et al. 2003). 
   The presences of atopic dermatitis and serum sIgE to inhalant allergens in early life 
were independent risk factors for BHR.  These findings are in accordance with a recent 
birth cohort study from Germany, in which BHR at school age was significantly 
associated with sensitisation to perennial allergens in early life (Illi et al. 2006). In 
contrast, Wennergren et al. did not find any association between early atopy and BHR at 
the age of 10 years in children who had been hospitalized for wheezing in infancy 
(Wennergren et al. 1997), but in line with the present study, maternal smoking during 
pregnancy was a significant predictor of BHR in adolescence (Goksör et al. 2007). 
Although there is some evidence that in utero exposure to tobacco smoke may increase 
BHR which may continue through childhood (Cook et al. 1998), the presence of many 
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factors like early-life passive smoking and later active smoking complicate the 
interpretation of the results (Cook et al. 1998, Lodrup Carlsen et al. 2001).  In the 
present study, the association between maternal smoking during pregnancy and BHR in 
teenage years was significant even after adjustment for passive smoking in infancy, and 
none of the children were smokers at the time of the study visit.  However, in contrast to 
the Finnish follow-up study which continued until adulthood, no associations were seen 
between exposure to environmental tobacco smoke in infancy and abnormal lung 
function (Piippo-Savolainen et al. 2006). 
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7. SUMMARY AND CONCLUSIONS 
 
   In the present prospective follow-up study after hospitalization for wheezing at less 
than two years of age, teenage asthma was common, being present in 40 % of the 
children. Persistent childhood asthma, i.e. asthma at all three follow-up visits at pre-
school age, at school age and in teenage years was present in 25 % of the children 
followed-up for 11 years. Most of the children with asthma were sensitized to at least 
one aeroallergen. 
   Compared to 4-5 % asthma prevalence in the child population in Eastern Finland, the 
prevalences of both, teenage asthma and persistent childhood asthma were elevated after 
both RSV- and rhinovirus-related hospitalization for wheezing in infancy. RSV 
aetiology of early wheezing was related to a better long-term outcome than wheezing 
with rhinoviruses or other viruses, though the difference did not reach statistical 
significance.  
   When tested in the teenage years, lung function assessed by FVS was within normal 
limits compared to gender- specific and height-related reference values for Finnish 
children. Children with teenage asthma or children with persistent childhood asthma had 
higher FVC values and lower FEV1/FVC values than had similar aged children with no 
asthma or persistent asthma. Further, children with RSV-related early wheezing had 
lower FVC values and higher FEV1/FVC values compared to other children raising the 
possibility that the difference might have been related to the susceptibility to early 
wheezing. However, lung function in infancy was not measured, and though only minor 
evidence was found that the children who would have later persistent asthma may 
respond better than the children without future persistent asthma to bronchodilators 
during the acute viral wheeze in infancy, the overall clinical responses to 
bronchodilators did not differ between these groups. 
   Non-specific early markers of atopy, atopic dermatitis in infancy and elevated serum 
total IgE were predictive of teenage asthma and persistent asthma. It was rare for there 
to be any allergen-specific IgE to inhalant allergens at the time of the index episode of 
wheezing, but if present, it was highly predictive for teenage asthma and persistent 
asthma as well as bronchial hyper-reactivity in the teenage years. The presence of 
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allergen-specific IgE to food allergens was common, and sensitization to cow's milk 
was predictive of teenage asthma and sensitization to wheat highly predictive for both 
teenage asthma and persistent childhood asthma. The present study failed to show any 
associations between family history of asthma or atopy and teenage asthma and 
persistent childhood asthma. 
   Early sensitization to cats and dogs was predictive for later asthma. However, simple 
early exposure to cats and dogs in contrast, was not related to any increased risk of 
atopic sensitization or the subsequent development of asthma in childhood. Exposure to 
environmental tobacco smoke in infancy was not related to abnormal lung function or 
bronchial hyper-reactivity at age 12 years, but maternal smoking during pregnancy 
increased the risk of bronchial hyper-reactivity. 
   With the selected cut-off points, elevated blood eosinophils and elevated eosinophil 
cationic protein in serum and in nasopharyngeal aspirate were found to be non-sensitive, 
but rather specific markers in recognizing wheezing infants at risk of chronic asthma. 
Elevated levels of eosinophil cationic protein in nasopharyngeal samples seemed to 
identify children at risk, and these children were not found by the other two markers. In 
addition, elevated levels of nasopharyngeal eosinophil cationic protein in infancy were 
an independent risk factor of persistent childhood asthma, which may suggest that 
eosinophil cationic protein, when present in respiratory secretions, is better at reflecting 
the airway pathology in children at high risk of chronic asthma than can be achieved by 
monitoring blood eosinophils or eosinophil cationic protein in serum. 
   In conclusion, teenage asthma is common after hospitalization for wheezing in 
infancy. The most important risk factors for both teenage asthma and persistent 
childhood asthma are early atopic dermatitis and early sensitization to inhalant allergens 
as well as early sensitization to wheat. Elevated markers of eosinophil activity in 
infancy predict later asthma, in particular active asthma lasting from early childhood at 
least until the teenage years. The level of eosinophil cationic protein in respiratory 
secretions was elevated in infants who would later develop asthma, pointing to the 
presence of airway eosinophilia in a subgroup of children at age 1-2 years. Rhinovirus-
induced early wheezing serves as a marker identifying children with an increasing 
number of asthma risk factors, though it is not an independent risk factor for asthma. 
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